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1. Abstract 
 
IL-1R8 is an Interleukin-1 receptor family member that acts as a negative regulator of 
IL-1 family receptor and Toll-like receptor (TLR) signaling. Both murine and human NK 
cells express high levels of IL-1R8 but its functional role in this cell type has not been 
described so far. Natural Killer (NK) cells are innate lymphoid-derived cells and are able to 
recognize damaged, stressed, viral infected or tumor cells, which express ligands interacting 
with activating NK cell receptors.  The expression of IL1R8 in NK cells prompted us to 
analyze its potential role in controlling NK cell effector functions. 
Expression analysis showed that IL-1R8 was acquired during differentiation in human 
and murine NK cells. IL-1R8 deficiency in the mouse was associated with higher frequency 
and absolute number of mature NK cells in blood, spleen, bone marrow and liver. Moreover, 
IL-1R8 deficient NK cells display an increased Interferonγ (IFNγ), Granzyme B and Fas 
ligand expression and degranulation. IL-18, which is a key regulator of NK cell activities and 
can be targeted by IL-1R8, was responsible for this phenotype. Indeed, IL-1R8 regulated IL-
18 axis during NK cell differentiation and activation and IL-18-dependent activation of 
mTOR and JNK pathways increased in IL-1R8-deficient NK cells.  
To assess the role of IL-1R8 in NK cells in pathology, we used models of 3-
methylcholanthrene (MCA)-induced lung metastasis, colon cancer-derived liver metastasis 
and diethylnitrosamine (DEN)-induced hepatocellular carcinoma. The number and dimension 
of liver and lung metastasis and the liver disease severity were significantly reduced in Il1r8-/- 
mice. The depletion of NK cells in these models totally abrogated the protection observed in 
Il1r8-/- mice. Finally, we investigated the role of IL-1R8 in NK cell antiviral activity, in a 
model of murine cytomegalovirus (MCMV) infection. Il1r8-/- mice showed an improved virus 
control in the liver and the protection was associated with enhanced NK cell degranulation 
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and IFNγ production. The adoptive transfer of Il1r8-/- NK cells conferred protection in both 
metastasis and viral infection models. 
Collectively, these results showed that IL-1R8 played a non-redundant role in the 
regulation of NK cell development and effector functions by tuning IL-18-dependent 
activities. IL-1R8 therefore emerges as a novel checkpoint molecule modulating NK cell 
antitumoral and antiviral potential. Preclinical models showed that the inactivation of IL-1R8 
unleashed NK cell effector functions, unveiling IL-1R8 as a potential immunotherapy target 
in the context of cancer and viral infections.  
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2. Introduction 
 
 
2.1 Interleukin-1 receptor 8 (IL-1R8) 
2.1.1 The IL-1 family  
 
Interleukin-1 receptor family members (ILRs) and Toll Like Receptors (TLRs) belong to a 
superfamily characterized by a common intracellular signalling domain, named Toll-IL-1 
resistance (TIR) domain [1], and extracellular Ig-like domains or leucine-rich repeats [2]. 
ILRs and TLRs are phylogenetically conserved proteins involved in the initiation and 
amplification of inflammation and innate and adaptive immune responses. TLRs work as 
sensors for exogenous infectious agents and host tissue injury, recognizing specific pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). 
The ILR subfamily is composed by receptors and accessory proteins (AcP) for the cytokines 
of the IL-1 family. A novel nomenclature of ILRs has been recently proposed [3] and it is as 
follows: IL-1R1 (IL-1RI), IL-1R2 (IL-1RII), IL-1R3 (IL-1RAcP), IL-1R4 (ST2), IL-1R5 (IL-
18Rα), IL-1R6 (IL-1Rrp2, IL-36R), IL-1R7 (IL- 18Rβ), IL-1R8 (also known as TIR8 or 
SIGIRR), IL-1R9 (TIGIRR- 2), IL-1R10 (TIGIRR-1). The IL-1 system includes molecules 
with agonist activity (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ), three receptor 
antagonists (IL-1Ra, IL-36Ra, and IL-38), and an anti-inflammatory cytokine (IL-37) (Figure 
1).  
ILR and TLR signaling covers a wide spectrum of functions in several tissues and cell types, 
ranging from tissue homeostasis regulation to protective responses against infections and 
modulation of inflammation. Given the huge capacity of ILR and TLR pathways to drive 
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inflammatory responses, the strict regulation of this system plays a significant role in both 
physiological and pathological conditions.  
Upon ligand binding, TLRs as well as ILRs dimerize through their TIR domains, inducing the 
recruitment of TIR domain containing adapter proteins, in particular MyD88, MAL, TRIF, 
TRAM and SARM, which couple to downstream protein kinases (e.g. IL-1R associated 
kinases (IRAKs), and tumor necrosis factor receptor-associated factor 6 (TRAF6)). The signal 
leads to the activation of key transcription factors associated with inflammatory and immune 
responses, such as nuclear factor-κB (NFkB), activator protein-1 (AP-1), c-Jun N-terminal 
kinase (JNK), p38 mitogen-associated protein kinase, extracellular signal-regulated kinases  
 
 
Figure 1. Members of the IL-1 and Toll-like receptor family. 
IL-1 family members comprise receptors (IL-1R1, IL-1R4, IL-1R5, IL-1R6, IL-1R7, IL-1R9 and IL-1R10). The 
IL-1 system includes an accessory protein (IL-1R3), receptors that work as negative regulators (IL-1R8 and IL-
1R2), molecules with agonist activity (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ), three receptor 
antagonists (IL-1Ra, IL-36Ra, and IL-38), and an anti-inflammatory cytokine (IL-37). IL-1 and Toll-like 
receptors all share a conserved TIR domain, that shows two mutations in IL-1R8. 
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(ERKs), mitogen-activated protein kinases (MAPKs), and members of the interferon (IFN)-
regulatory factor (IRF) [4-6].  
ILR and TLR functional activation is modulated by several and diverse mechanisms. Among 
these, IL-1R2 exerts regulatory functions acting as decoy receptor for IL-1, dominant negative 
molecule and scavenger [7, 8]. In addition, it is also present in the cytoplasm where it binds 
pro-IL-1α, preventing its cleavage and activation [9]. IL-1R8, also known as TIR8 or 
SIGIRR, whose function will be detailed, is a fringe member of the family that lacks 
conventional signalling capacities and works as a negative regulator of the family, acting 
intracellularly. Available information suggests that IL-1R8 interferes with the association of 
TIR-containing adaptor molecules to the receptor complex, thus dampening the signalling 
pathway leading to signal transduction [10, 11]. In addition, IL-1R8 is a component of the 
receptor recognizing the anti-inflammatory cytokine IL-37 [12]. IL-37 is an anti-
inflammatory cytokine that acts as a natural brake of inflammation, signaling through IL-
1R5/IL-18Rα and IL-1R8 was recently described as a co-receptor, required for the formation 
of the tripartite complex IL-37-IL-1R5/IL-18Rα-IL-1R8 [12]. IL-18BP is an extracellular 
protein that binds IL-18, preventing its interaction with the receptor IL-1R5/IL-18R, and thus 
neutralizing its activity [13-15]. IL-1Ra and IL-36Ra are receptor antagonists that bind IL-
1R1 and IL-1R6, respectively [6, 16-19].  
Intracellular negative regulators of ILRs and TLRs and specific miRNAs (miR-155, miR-21, 
miR-146a, miR-132, miR-9, and miR-147) targeting ILR and TLR signaling have been also 
reported [20-24]. The abundance of these regulatory mechanisms highlights the relevance of 
the negative regulation of both ILRs and TLRs, which if uncontrolled, may activate 
detrimental inflammation and cause tissue damage. For instance, local and systemic 
inflammation induced by IL-1 underlay a broad list of diseases, ranging from rheumatic 
diseases and autoinflammatory syndromes to cardiovascular diseases, type 2 diabetes and 
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infections and sepsis, and targeting of IL-1 has relevant therapeutic implications [25-28]. 
2.1.2 IL-1R8 (TIR8/SIGIRR)-mediated regulation of ILRs and TLRs 
 
IL-1R8 was identified by our group and reported as TIR8 in 1998 (Accession number: 
AF113795), and in parallel by John Sims' group in 1999 and reported as SIGIRR (Figure 1) 
[29]. IL-1R8 is localized on human chromosome 11 and murine chromosome 7 and is 
composed by ten exons in humans and nine exons in the mouse. [29]. The human protein is 
410 aminoacid-long and displays unique features compared with other ILRs. Indeed, it is 
composed of a single extracellular Ig domain, in contrast with the other family members, 
which have three, a transmembrane domain, a cytoplasmic TIR domain and an unusually long 
tail (95 residues), which is missing in other TIR domain-containing receptors. The IL-1R8 
TIR domain lacks two conserved residues (Ser447 and Tyr536), which are replaced by 
Cys222 and Leu305 suggesting unconventional signaling [30, 31].  
IL-1R8 sequence is highly conserved among vertebrates, from chicken to human in terms of 
sequence and pattern of expression. Human and murine protein sequences are 82% identical 
and share 23% overall identity with IL-1R1 [32].  
IL-1R8 has 5 potential N-glycosylation sites in the extracellular domain in humans and 4 in 
the mouse and is extensively N- and O-glycosylated. It was recently showed that loss of N-
linked glycosylation was associated with an inactive isoform of IL-1R8, generated by 
alternative splicing in colon cancer cells. Moreover, loss of complex glycan modifications 
was sufficient to suppress IL-1R8 activity in vivo, highlighting that post-transcriptional 
modifications are required for the functional activity of IL-1R8 [33]. 
IL-1R8 is widely expressed in several epithelial tissues, in particular by epithelial cells of the  
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Figure 2. IL-1R8 regulatory function. 
IL-1R8 negatively regulates IL-1 and Toll-like receptors and it is therefore involved in the modulation of cell 
survival, proliferation and inflammation. It exerts it inhibitory activity directly acting on cell-membrane 
receptors but also TIR-containing adaptor molecules (e.g. Myd88). It inhibits IL-1 and TLR downstream 
pathways such as MAPK and mTOR pathways. With a different mechanism, it is also necessary for the signaling 
of the anti-inflammatory cytokine IL-37, therefore acting both as a negative regulator and an active anti-
inflammatory mediator.  
 
kidney, digestive tract, liver, lung, and in lymphoid organs. Among leukocytes, it is expressed 
by monocytes, B and T lymphocytes, dendritic cells and NK cells [29, 34]. Little is known 
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both IL-1R8 mRNA and protein expression are reduced in inflammatory conditions.  
IL-1R8 exerts its regulatory activity by inhibiting NFκB and JNK activation induced by TIR-
containing ILRs or TLRs upon ligand binding, but not by other receptors such as Tumor 
necrosis factor (TNF) receptors. In particular, IL-1R8 was shown to modulate the activation 
of IL-1R1, IL-1R5/IL-18Rα, IL-1R4/ST2, TLR4, TLR7, TLR9, TLR3 and TLR1/2 (Figure 2) 
[30, 31, 35-37]. 
The molecular mechanism involved in IL-1R8-mediated regulation of ILRs and TLRs is still 
poorly characterized. Upon stimulation with IL-1, the IL-1R8 extracellular domain was 
shown to block the dimerization between IL-1R1 and IL-1R3/IL-1RAcP, and the intracellular 
 
  
 
Figure 3. IL-1R8 activity in different cell types. 
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IL-1R8 is expressed by several cell types and exerts cell- and site-specific functions, which are also dependent 
on the context and involve diverse upstream mediators. It inhibits NK cell and ILC1 effector functions, it 
regulates T cell activation and polarization and it modulates myeloid cell, platelet and epithelial cell activation. 
 
TIR domain was shown to bind the TIR-containing adaptor protein Myd88 and downstream 
signaling molecules (IRAK and TRAF6), thus modulating IL-1 signalling [31, 35]. Similarly, 
the targeting of IL-1R4/ST2 was shown to be dependent on both the extracellular 
immunoglobulin and TIR domains [37]. In contrast, only the TIR domain was necessary for 
the inhibition of TLR4 signalling, as demonstrated by mutagenesis studies [31, 35].  
JNK and mTOR phosphorylation were shown to be enhanced in IL-1R8 deficient Th17 cells. 
IL-1R8 is therefore crucial in the modulation of metabolism, differentiation, expansion and 
effector functions of Th17 cells (Figure 2) [38]. IL-1R8 was also demonstrated to target 
mTOR phosphorylation driven by IL-1 or TLR agonists derived from commensal flora, in 
intestinal epithelial cells [39]. IL-1R8 therefore emerges as a regulator of the cell cycle, 
playing a crucial role in homeostatic conditions.  
Thus, these results indicate that IL-1R8 interferes with the formation of TIR domain 
signalosome, preventing the dimerization of receptors, accessory proteins and adaptor 
molecules, and blocking TLR and IL-1 family signaling (Figure 2, 3).  
 
IL-37 signaling 
IL-1R8 was considered an orphan receptor, lacking a specific ligand. IL-37 has been recently 
demonstrated to bind IL-1R8, to generate the tripartite complex IL-37-IL-1R5/IL-18Rα-IL-
1R8 [12]. IL-37 is an anti-inflammatory cytokine that dampens the inflammatory response 
triggered by TLRs and cytokines in peripheral blood mononuclear cells (PBMCs), in 
macrophages and epithelial cells and IL-37-transgenic mice (IL-37tg mice) are protected in 
different inflammatory pathological conditions [40]. Recently, advanced imaging analysis 
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revealed a rapid interaction of IL-37 with both IL-1R5/IL-18Rα and IL-1R8 in human 
PBMCs and bone marrow-derived macrophages (BMDMs) of IL-37tg mice upon stimulation 
with lipopolysaccharide (LPS) [12]. IL-1R8 and IL-1R5/IL-18Rα were both required to 
support the anti-inflammatory activity of IL-37 in PBMCs, THP-1 macrophages and A549 
epithelial cells. Finally, proteomic and transcriptomic analysis demonstrated that the IL-37-
IL-1R5/IL-18Rα-IL-1R8 complex triggered multiple signalling events leading to anti-
inflammatory responses, such as inhibition of MAPK, NFκB, mTOR, TAK1 and Fyn and 
activation of STAT3, Mer, PTEN and p62(dok).  
Thus, IL-1R8 acts as a co-receptor for IL-1R5/IL-18Rα upon IL-37 binding and it is required 
for the anti-inflammatory activity of IL-37 [12, 41]. This mechanism is relevant in vivo, since 
IL-1R8-deficiency abolished the protection of IL-37tg mice against endotoxin challenge or 
the protective role of IL-37 in a model of non-resolving A. fumigatus infection and pulmonary 
damage [12, 42]. Moreover, in a model of OVA-induced asthma, IL-37-driven anti-
inflammatory effects were abolished in mice lacking either IL-1R5/IL-18Rα or IL-1R8 [43].  
Thus, these results demonstrate that IL-1R8 is not only a negative regulator, but also part of 
the receptor complex of the anti-inflammatory cytokine IL-37 and mediates an anti-
inflammatory signaling activation (Figure 3).  
2.1.3 Role of IL-1R8 in infections 
 
IL-1R8 emerged as a key molecule in bacterial and fungal infections, playing a crucial role in 
the regulation of pathogen-induced TLR and ILR responses and in the modulation of 
inflammation and tissue damage (Figure 4).  
In Mycobacterium tuberculosis infection, IL-1R8-deficient mice exhibited higher mortality, 
which was driven by an exacerbated systemic inflammatory response, even if no difference in 
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tissue bacterial load in the lung, liver or spleen was observed. Indeed, IL-R8 deficient mice 
presented an overwhelming inflammatory response, characterized by enhanced macrophage 
and neutrophil lung infiltration and increased systemic levels of inflammatory cytokines. [44]. 
In a model of keratitis induced by P. aeruginosa, IL-1R8 was involved in the regulation of 
IL-1R1 and TLR4 signalling in T cells, and dampening Th1 response, thus preventing tissue 
damage and promoting resistance to infection [45]. Similarly, in acute lung infections caused 
by P. aeruginosa, IL-1R8-deficient mice showed increased susceptibility to the pathogen, in 
terms of mortality and bacterial load, increased production of pro-inflammatory cytokines and 
the phenotype was dependent on IL-1 signaling [46]. 
In Candida albicans or Aspergillus fumigatus infections, the absence of IL-1R8 led to 
increased susceptibility to mucosal and disseminated or lung infections, respectively [47]. IL-
1R8-deficient mice showed increased mortality and fungal burden, enhanced activation of IL-
1 signalling, Th17 and γδ T cell response and reduced Treg activation. [47]. 
 The role of IL-1R8 is therefore attributable to the negative regulation of IL-1 
signalling in P. aeruginosa, C. albicans and M. tubercolosis infections, since IL-1 
neutralization was sufficient to abolish the phenotype in IL-1R8-deficient mice.  
 The relevance of these data in the mouse was supported by a case-population study 
design in Vietnam, showing that 3 SNPs (rs10902158, rs7105848, rs7111432) in IL-1R8 gene 
correlated with the development of both pulmonary tuberculosis and tuberculous meningitis. 
Moreover, coinheritance of these SNPs with previously identified polymorphisms in TLR2 
and TIRAP was associated with enhanced risk of susceptibility [48]. 
 The protective role of IL-1R8 in the infections mentioned above is due to the 
regulation of ILR and TLR signalling that potentially cause detrimental inflammation and 
tissue damage. However, in a model of experimental urinary tract infection (UTI) induced by 
uropathogenic Escherichia coli, IL-1R8-deficient mice displayed reduced renal bacteria 
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outgrowth and diminished renal dysfunction [49].  
 Similarly, during pneumonia and sepsis induced by Streptococcus pneumoniae in the 
mouse, IL-1R8-deficiency was associated with delayed mortality, reduced bacterial load in 
the lungs and reduced dissemination of the infection [50]. Increased interstitial and 
perivascular inflammation was observed in IL-1R8-deficient lungs mice in the early phase of 
infection. Thus, IL-1R8 suppressed the protective antibacterial immune response in S. 
pneumoniae induced pneumonia [50]. 
 Murine models of Citrobacter rodentium infection resemble human intestinal 
infections driven by enteric bacterial pathogens such as enterohemorrhagic E. coli (EHEC) 
and Salmonella typhimurium. Upon Citrobacter rodentium infection, IL-1R8-deficiency 
correlated with accelerated intestinal epithelial cell (IEC) proliferation and enhanced pro-
inflammatory and anti-microbial response. However, IL-1R8 was shown to be protective in 
this model, in terms of weight loss, intestinal damage, colitis score and intestinal bacterial 
burden. IL-1R8 protective function was dependent on IL-1R1-MyD88 signalling, indicating 
that IL-1R1 may be the key receptor targeted by IL-1R8 in this context. Infected IL-1R8-
deficient mice underwent a more rapid and dramatic loss of commensal flora, compared with 
controls. In infected mice, the microbiota depletion was directly dependent on the exacerbated 
antimicrobial response occurring in IL-1R8-deficient mice that favored pathogen 
colonization. Thus, IL-1R8-mediated regulation of IECs is responsible for the inhibition of a 
strong anti-microbial response that would otherwise lead to a rapid depletion of the 
commensal microbiota, during intestinal infection. In turn, the absence of competing 
microflora would favor the colonization by bacterial pathogens [51]. 
Recently, it was observed that IL-1R8 is highly expressed in both human and murine platelets 
and megakaryocytes and plays a key role in the regulation of platelet activation in 
inflammation and thromboembolism [52]. In particular, IL-1R8-deficient platelets displayed a 
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hyperactivation in basal conditions, in terms of active α2bβ3 and P-selectin surface 
expression. IL-1R8-deficiency was also associated to increased platelet/neutrophil aggregate 
formation, induced by LPS, IL-1β or IL-18 in vitro and in a systemic LPS-induced 
inflammation model in vivo [52]. Hyperactivity of platelets in absence of IL-1R8 was 
demonstrated to be dependent on IL-1 signalling, since the phenotype was abrogated in Il1r8-
/-/Il1r1-/- mice. Importantly, in patients with SIRS/sepsis, which is associated to platelet 
dysfunction [53], IL-1R8 surface expression was significantly down regulated compared to 
healthy controls and its expression level was associated with the severity of the disease. In 
line with this, murine platelets and megakaryocytes showed a reduced expression of IL-1R8 
upon treatment with LPS in vitro and in vivo. LPS induced microparticle (MP) release from 
platelets and it was observed that MP derived from LPS-stimulated platelets or from serum of 
septic patients expressed higher levels of IL-1R8 compared to controls, suggesting a shedding 
of the receptor in inflammatory conditions through MP release [52]. These data elucidate a 
novel function of IL-1R8, characterizing its non-redundant role in the regulation of 
thrombocyte function.   
Thus, IL-1R8 plays a crucial role in favoring the maintenance of a delicate equilibrium 
between the protective immune response against infections and the development of 
detrimental inflammation and host injury. The activity of IL-1R8 is therefore strictly 
dependent on the context and several lines of evidence suggest that during homeostasis the 
constitutive expression of IL-1R8 protects against inappropriate responses, whereas its down-
regulation during acute inflammatory stimulation enhances the efficacy but also pathogenic 
potential of antibacterial host defense.  
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2.1.4 role of IL-1R8 in the CNS 
 
IL-1R8 is expressed in the brain by neurons, microglia and astrocytes and it was shown to be 
involved in the regulation of LPS responsiveness in the brain (Figure 4) [17, 34, 54]. Indeed, 
IL-1R8-deficiency was associated with a massive LPS-induced inflammation in the brain. In 
response to LPS, IL-1R8 negatively regulated CD40, ICAM and cytokine (IL-6 and TNFα) 
mRNA expression in microglial cells and cytokine production in hippocampal tissue [55]. 
In addition, it has been observed that cognitive and synaptic functions, such as novel object 
recognition, spatial reference memory, and long-term potentiation (LTP) were impaired in IL-
1R8-deficient mice, in absence of any external stimulus. This was associated with a higher 
expression of IL-1R1 and TLR4 and an enhanced activation of downstream signalling 
molecules (IRAK1, c-Jun, JNK and NFκB) [56]. IL-1α and high mobility group box 1 
(HMGB1), which activate IL-1R1 and TLR4, respectively, were proposed to play a central 
role in the phenotype observed [56]. Moreover, IL-1R6 antagonist (IL-36Ra) inhibits the IL-
1- and LPS-induced inflammatory response in glial cells and this effect was absent in mixed 
glia prepared from IL-1R8-deficient mice, suggesting the involvement of IL-1R8 in the anti-
inflammatory activity of IL-36Ra, possibly mediated through the production of IL-4 [17]. 
Finally, a recent study showed that IL-1R8 acted as a negative regulator of β-amyloid (Aβ) 
peptide-induced TLR2 signalling in the brain. Aβ is the main component of neuritic plaques 
in Alzheimer’s disease (AD) and the primary mediator of the AD-associated 
neuroinflammation [57]. Anti-TLR2 treatment of microglia attenuated the inflammatory 
response and the impairment in LTP, both induced by Aβ, confirming the central role of 
TLR2 in the Aβ-induced neuroinflammation. [57]. These findings highlighted the key role of 
IL-1R8 in the modulation of TLR2-induced inflammation in the brain and its relevance in a 
potential therapeutic approach targeting TLR2 in AD-related pathology. 
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A recent study elucidated the molecular mechanisms underlying cognitive and synaptic 
function impairment in absence of IL-1R8 [58]. IL-1R8-deficiency affected neuron synapse 
morphology, plasticity and function, through the hyperactivation of IL-1R1 signaling. Indeed, 
IL-1R8-deficient hippocampal neurons exhibited a defective synaptic plasticity and function, 
in terms of an increased number of immature, thin spines and a decreased number of mature, 
mushroom spines along with a significant reduction of spine width, and reduced amplitude of 
miniature excitatory postsynaptic currents. The unleashed IL-1R1 activation in absence of IL-
1R8 was shown to impair spine morphogenesis and plasticity through the PI3K/AKT/mTOR 
pathway by increasing the expression of methyl-CpG-binding protein 2 (MeCP2), a 
synaptopathy protein involved in neurological diseases characterized by defective plasticity, 
impaired cognition and intellectual disability, such as Rett syndrome and MeCP2 duplication 
syndrome [59]. IL-1 pharmacological inhibition with IL-1Ra (Anakinra) or IL-1R1 genetic 
inactivation rescued MeCP2 expression and cognitive deficit, suggesting that the 
physiological activation level of IL-1 signaling is fundamental for the proper neural long-term 
potentiation [58]. Interestingly in this context, IL-1 inhibition in cryopyrin-associated periodic 
syndrome (CAPS) patients, not only reduced signs and symptoms of IL-1-dependent 
inflammation, but also reversed mental defects [60]. These results thus identify IL-1R8 as a 
novel molecular player involved in synaptopathies acting by fine tuning IL-1 activity in 
neurons. 
2.1.5 Role of IL-1R8 in sterile inflammation  
 
IL-1R8 in autoimmunity 
ILRs and TLRs are key players in the pathogenic mechanisms of autoimmune disorders and 
IL-1R8 emerged as a crucial regulator in this context (Figure 4). In particular, IL-1 regulates 
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the differentiation and function of Th17 cells, which are involved in inflammatory diseases 
such as rheumatoid arthritis (RA), multiple sclerosis, psoriasis, and inflammatory bowel 
disease (IBD) [61]. IL-33 is a driver of type 2 inflammatory responses and is implicated in 
allergy and asthma [62]. 
Gulen et al. showed that IL-1R8 was induced during Th17 cell polarization and that it 
controlled Th17 cell differentiation, expansion and effector functions, through the direct 
inhibition of IL-1 signalling in T cells. An increased phosphorylation rate of JNK, mTOR and 
4EBP1 was observed in IL-1R8-deficient T cells, upon stimulation with IL-1. In particular, 
IL-1-induced mTOR pathway was critical for the IL-1R8-mediated modulation of Th17 
response. Thus, IL-1R8 emerged as a key regulator of IL-1 activity in Th17 cells and it was 
also observed to be involved in the Th17-mediated development of central nervous system 
(CNS) autoimmune disorders. Indeed, IL-1R8-deficient mice revealed higher susceptibility to 
experimental autoimmune encephalomyelitis (EAE), due to an increased Th17 infiltrate in the 
CNS and enhanced Th17 polarization and pathogenic functions [38]. 
In rheumatoid arthritis models, IL-1R8-deficient mice were shown to develop a more severe 
disease, and this correlated with an increased cellular infiltration in the affected joints. IL-1Ra 
treatment reduced the susceptibility of IL-1R8-deficient mice in zymosan-induced arthritis, 
suggesting that IL-1 played a central role in this model.  Moreover, IL-1R8 was shown to 
suppress the spontaneous release of cytokines in human RA synovial cells in vitro. [63]. In 
agreement with this study, IL-1R8 expression was reduced in peripheral blood of patients 
with psoriatic arthritis, compared with healthy donors [64]. Moreover, IL-1R8 deficiency 
caused enhanced susceptibility to psoriasis, associated to increased infiltration and activation 
of γδ T cells, in both Aldara- and rIL-23-induced psoriasis models. Interestingly, IL-R8 
directly modulated IL-1-driven IL-17A expression by γδ T cells in vitro and in vivo and IL-
17A depletion abolished the phenotype observed in IL-1R8-deficient mice [65].  
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Increasing evidences implicated IL-1R8 in the pathogenesis of systemic lupus erythematosus. 
Indeed, altered TLR signalling in DCs and B cells is one of the driving mechanisms of this 
autoimmune disorder. In particular, immune complexes containing the lupus autoantigen 
U1snRNP or nucleosomes activate DCs and autoreactive B-cells via TLR7 and TLR9, 
respectively [66, 67]. In the mouse IL-1R8-deficiency alone did not induce autoimmunity 
against DNA. However IL-1R8-deficiency in C57BL/6lpr/lpr mice, which develop delayed 
autoimmunity due to impaired Fas-induced apoptosis of autoreactive B and T cells, caused 
increased activation of DCs and B cells and production of proinflammatory cytokines and B 
cell antiapoptotic mediators. IL-1R8-deficient C57BL/6lpr/lpr mice also displayed and 
increased production of autoantibodies (anti-dsDNAIgG, anti-nucleosome, anti-Sm antigen, 
anti-snRNP, and rheumatoid factor) and presented a massive lymphoproliferative disorder, 
associated with enhanced autoimmune lung disease, lupus nephritis and 
hypergammaglobulinemia, compared with IL-1R8-competent C57BL/6lpr/lpr controls [68]. In 
line with this, IL-1R8 was also protective in a model of hydrocarbon oil-induced lupus, in 
which it modulated TLR7-mediated activation of DCs and expansion of autoreactive 
lymphocyte clones. IL-1R8 is therefore involved in the regulation of DC and B cell 
activation, by preventing exacerbated autoimmune reactions, lymphoproliferation and tissue 
damage in SLE [69]. The data in the mouse were supported by recent analysis of IL-1R8 
involvement in SLE in human. A case study of a cohort of SLE patients revealed a reduced 
frequency of IL-1R8+ CD4+ T cells in the peripheral blood of SLE patients compared with 
healthy individuals. Moreover, the frequency of IL-1R8+ CD4+ T cells was further reduced in 
SLE patients with nephritis, compared with those without nephritis [70]. Moreover, a genetic 
variant of IL-1R8 (rs7396562) was identified and it was demonstrated to correlate with the 
susceptibility to SLE, in a Chinese population [71].  
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IL-1R8-mediated regulation in asthma and allergy 
IL-33 signalling is a key driver of type 2 immunity, which favors protective immune 
responses in parasite infections and tissue repair but is also involved in pathological 
conditions such as asthma, allergy and eosinophilia (Figure 4) [72]. IL-33 receptor (IL-
1R4/ST2) affects innate and adaptive lymphoid cells (ILCs and Th2), inducing the production 
of type 2 cytokines (IL-4, IL-5, IL-13), and can be targeted by IL-1R8. Indeed, IL-1R8 
inhibits IL-33-mediated signalling in Th2 cells, controlling the production of type 2 cytokines 
in vitro and in vivo [37]. IL-1R8-deficient mice were shown to be hyper responsive to IL-33, 
in terms of lung inflammation, splenomegaly and increased serum levels of IL-5 and IL-13 
[37]. Moreover, in a model of allergic pulmonary inflammation induced by OVA, IL-1R8 
deficiency was associated with increased leukocyte lung infiltration, IL-5 and IL-4 levels and 
OVA-specific IgE induction, due to an exacerbated Th2 response [37]. These results indicate 
that IL-1R8 serves as a negative feedback control in Th2-polarization and restimulation, thus 
controlling allergic inflammatory responses. However, a genetic study performed on a cohort 
of Japanese asthma patients revealed that none of the alleles or haplotypes of IL-1R8 
identified were associated with asthma susceptibility or asthma-related conditions [73]. 
 
Role of IL-1R8 in kidney sterile inflammation  
IL-1R8 is expressed at high levels in the kidney, in particular by tubular epithelial cells. 
Immunohistochemical analysis revealed extensive IL-1R8 positivity in the majority of tubular 
epithelial cells of the renal cortex, showing a predominant expression at the apical side of 
renal proximal tubules (Figure 4) [36]. IL-1R8 was shown to be a key player in sterile kidney 
diseases, by regulating TLR activation by nucleosomes and DAMPs, released during ischemic 
cell necrosis and associated with pathological conditions such as lupus nephritis, postischemic 
acute renal failure or kidney transplantation [68, 69, 74, 75].  
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In a postischemic renal failure model, IL-1R8 deficiency was associated with increased renal 
injury, due to a massive activation of myeloid cells, increased intrarenal cytokine and 
chemokine production and increased leukocyte recruitment. [74]. In line with this, in a mouse 
model of fully mismatched kidney allotransplantation, IL-1R8-deficient grafts were less 
tolerated compared with control grafts, leading to acute rejection. Moreover, IL-1R8-
deficiency was associated with an enhanced ILR- and TLR-driven post transplant kidney 
inflammatory response, in particular due to increased neutrophil and macrophage infiltrate 
and higher expression of TNFα and chemokines. The enhanced expansion and maturation of 
DCs observed in IL-1R8-deficient mice led to an amplified adaptive alloreactivity and 
reduced Treg cell development. Thus, IL-1R8 plays a key role in the regulation of the 
allogeneic immune response in situ and is involved in graft survival [75]. 
 
Role of IL-1R8 in intestinal inflammation 
IL-1R8 was demonstrated to be a key regulator of intestinal homeostasis. Intestinal epithelial 
cells (IECs) are intrinsically hypo-responsive to bacterial products, thus preventing 
exaggerate inflammatory responses against the commensal flora but also limiting the enteric 
host defense (Figure 4) [30]. On the other hand, gut microflora-mediated activation of ILRs 
and TLRs provides the survival signals for IECs and this pathway is targeted by IL-1R8, 
which is therefore involved in controlling proliferation and survival in colon crypts [76]. The 
specific role of IL-1R8 in the regulation of microflora and microflora-derived signaling in the 
intestinal barrier is quite controversial, probably because of the animal-house-dependent 
variations in the microflora, and needs to be further characterized.  
 In a model of sterile colitis, induced by dextran sodium sulfate (DSS), IL-1R8-
deficiency was associated with an exacerbated intestinal inflammation, in terms of weight 
loss, intestinal bleeding, local tissue damage and a reduced survival. This correlates with an 
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increased leukocyte infiltration in the intestine and higher level of proinflammatory cytokines 
(TNFα, IL-6, IL-1β, IL-12p40, IL-17), chemokines (CXCL1, CCL2) and prostaglandins. 
Experiments with bone marrow chimeric mice demonstrated that the regulatory function 
exerted by IL-1R8 occurs in epithelial cells, in both DSS- and enteric pathogen-induced 
colitis [30, 76]. 
2.1.6 Role of IL-1R8 in cancer 
 
Epidemiological studies have shown that chronic inflammation, both dependent on infectious 
agents or not, can increase the risk of cancer (Figure 4). The hallmarks of cancer-related 
inflammation are comparable to those observed in chronic inflammatory conditions: 
inflammatory cells and mediators are present in the tumor tissue and they are implicated in 
tissue repair, remodelling and angiogenesis. This 'smouldering inflammation' occurs even in 
tumors that are not directly caused by an inflammatory trigger. Cancer-related inflammation 
depends on two possible pathways: an intrinsic pathway, driven by oncogenic mutations that 
cause both neoplasia and inflammation, or an extrinsic pathway, driven by inflammatory 
conditions that favor tumor development (e.g. colitis-associated intestinal cancer) [77-80]. 
Several studies have revealed a crucial role of ILR and TLR signalling in this context, in 
which NFκB is one of the key orchestrators, and that IL-1R8 plays a protective role in the 
pathogenesis of cancer-related inflammation in different murine models of colon cancer [80].  
 
Colorectal cancer 
IL-1R8 function in cancer was first characterized in a model of colorectal cancer, induced by 
the treatment with the procarcinogen Azoxymethane (AOM), followed by Dextran sodium 
sulfate (DSS), which favors chronic inflammation [76, 81]. This model mimics intestinal 
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cancer that develops in chronic IBD patients, in particular Ulcerative Colitis patients. In the 
AOM-DSS colitis-associated cancer (CAC) model, IL-1R8-deficiency was associated with 
exacerbated inflammation in the intestine, leading to increased susceptibility to cancer 
development, in terms of number, size, and severity of lesions. IL-1R8 negatively regulated 
intestinal permeability, in situ production of proinflammatory cytokines and chemokines and 
prostaglandin E2, and the expression of NFκB-induced genes involved in cell survival and 
proliferation (Bcl-xL and Cyclin D1) [76, 81]. In this context, chemokines favored cancer 
progression, influencing the extent and type of leukocyte infiltrate (e.g. recruiting Th2 and 
Treg cells) and driving tumor cell and endothelial cell growth and migration [82, 83]. 
Moreover, increased levels of IL-10 and TGF-β were observed in tumors of IL-1R8-deficient 
mice, reflecting an immunosuppressive microenvironment that inhibited T cell-dependent 
antitumoral immunity [83]. IL-1R8 overexpression in gut epithelial cells abolished the 
susceptibility of IL-1R8-deficient mice to CAC development, suggesting that the regulatory 
activity of IL-1R8 in intestinal epithelial cells plays a central role in this model [76]. Since 
commensal microflora-derived stimuli are necessary for the homeostasis of colon epithelium 
and are involved in colitis-associated carcinogenesis, IL-1R8 regulation may be possibly 
dependent on its direct modulation of microbiota-activated TLRs [84]. However, IL-1R8-
mediated targeting of other TLR- and ILR-related pathways cannot be excluded in this model. 
 IL-1R8 involvement in colon cancer was also investigated in the genetic Apcmin/+ 
model, in which tumor initiation is caused by loss of heterozygosity (LOH) of the tumor 
suppressor Apc and which mimics the Familial Adenomatous Polyposis syndrome [85]. In 
Apcmin/+ mice, IL-1R8 deficiency led to an increased susceptibility to cancer development, 
due to a more sustained activation of the Akt/mTOR pathway, which plays a crucial role in 
tumor initiation [86]. In this model, IL-1R8 was demonstrated to exert an antitumoral activity 
by suppressing IL-1- and TLR-induced mTOR-mediated cell cycle progression and 
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consequent genetic instability [39]. 
 A recent study has investigated the role of IL-1R8 in human colorectal cancer, 
demonstrating that colon tumors express lower level of IL-1R8 compared with healthy tissues 
and that IL-1R8 is frequently inactivated in human colorectal cancer [33]. Indeed, Zhao et al. 
identified a dominant negative isoform of IL-1R8 (IL-1R8ΔE8) and RNA sequencing data 
demonstrated that the expression level of this isoform increased in human colon cancer, 
compared with healthy tissue. The IL-1R8 ΔE8 isoform originated from a transcript that lacks 
the exon 8 of the gene and exhibited compromised integrity of the TIR domain, increased 
retention in the cytoplasm and reduced N-linked glycosylation. The cytoplasmic retention 
caused a decrease in the cell surface expression of IL-1R8 and a consequent loss of its 
inhibitory activity. Moreover, IL-1R8 ΔE8 isoform was shown to be able to interact with full-
length IL-1R8, acting as an antagonist of IL-1R8 and thus suppressing its function. To 
investigate the mechanism responsible for IL-1R8 ΔE8 isoform synthesis in tumor cells, 
sequence analysis were performed and predicted that exon 8 would be intrinsically a “weak” 
exon, with high probability of exclusion. Exon 8 also displayed a binding site for CTCF, a 
factor that favors the inclusion of weak exons, and since the binding can be reduced by 
methylation, hypermethylation was proposed to be the strategy followed by cancer cells that 
leads to IL-1R8ΔE8 isoform expression. Indeed, treatment with decitabine, a methyltransferase 
inhibitor, reduced IL-1R8 ΔE8 isoform expression. To model the impact of IL-1R8 ΔE8 isoform 
in colon carcinogenesis in the mouse, gut epithelium-specific IL-1R8 transgenic mice were 
generated, expressing a mutant form of IL-1R8 (IL-1R8N85/101S) that mimics IL-1R8 ΔE8 
isoform or wild-type IL-1R8 as a control. In both AOM and AOM-DSS models, the presence 
of wild-type IL-1R8 in intestinal epithelial cells protected the mice from the development of 
colon cancer. On the contrary, mice expressing IL-1R8N85/101S isoform had the same 
phenotype as IL-1R8-deficient mice, suggesting that complex glycan modifications and cell 
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surface expression are necessary for IL-1R8 functional activity in vivo [33]. Thus, IL-1R8 
alternative splicing is an escape mechanism adopted by tumor cells to inactivate IL-1R8 
through the generation of a dominant negative isoform. 
 
Chronic lymphocytic leukemia  
Both genetic defects and microenvironment stimuli contribute to chronic lymphocytic 
leukemia (CLL) development and progression. Moreover, factors originating from the 
microenvironment are involved in the selection and expansion of the malignant clone [87, 
88]. Human malignant B cells expressed lower levels of IL-1R8 mRNA than normal B cells, 
and accordingly, in the well-established transgenic mouse model of CLL (TCL1), CD19+ B 
cells expressed lower levels of IL-1R8 mRNA transcript, compared with controls [88-91]. IL-
1R8-deficiency did not affect B cell compartment in healthy mice, whereas it correlated with 
an earlier and more severe appearance of monoclonal B cell expansion and a reduced mouse 
life span in TCL1 transgenic mice, mimicking the aggressive variant of human CLL [91]. 
These findings revealed IL-1R8 inhibitory role in CLL initiation and progression, even 
though the molecular mechanism is still unclear. Endogenous TLR or ILR ligands are known 
to be involved in CLL and may be candidate targets of IL-1R8. 
 
Breast cancer 
Recently, Campesato LF et al. identified IL-1R8 in breast cancer as a crucial 
immunomodulatory molecule, which upregulation in transformed breast epithelial cells leads 
to an impaired innate immune sensing and T cell response [92]. Gene transfer experiments in 
breast tumor cell lines have shown that IL-1R8 upregulation in transformed cells inhibits IL-
1-dependent NF-κB activation and expression of pro-inflammatory molecules. IL-1R8-
deficient mice were protected from the development of breast cancer in a genetic model 
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(MMTV-neu) and the number of lung metastasis was reduced. Experiments with bone 
marrow chimeric mice supported the predominant protective role of IL-1R8-deficiency in 
non-haematopoietic/tumor cells in this model. In particular in vitro and in vivo evidences 
demonstrated that IL-1R8 in tumor cells was responsible for shaping the tumor 
microenvironment and IL-1R8-deficiency was associated with higher frequency of DCs, NK 
cells and CD8+ T cells and lower proportions of TAMs [92]. In line with this, RNAseq 
analysis in 1102 clinical samples of breast tumors revealed that high IL-1R8 expression was 
associated with a non-T cell inflamed molecular signature, lower expression level of pro-
inflammatory cytokines and chemokines, DC and NK cell metagenes, components of the 
peptide-presenting machinery, cytolytic enzymes and type I IFN-induced genes. Collectively, 
these data indicate that IL-1R8 expression in breast tumors represent a novel tumor-mediated 
immunoevasion mechanism, affecting the mobilization and activation of immune cells and 
therefore tumor growth and metastatization [92]. These findings have important therapeutic 
implication and the blockade of IL-1R8 in breast tumor cells may represent a way to restore 
the innate immune response and T cell trafficking and activation in the tumor 
microenvironment. 
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Figure 4. Role of IL-1R8 in different contexts. 
IL-1R8-deficient mice showed that IL-1R8 is a crucial molecule regulating acute and chronic inflammation in 
several pathological conditions (listed in the figure). It is also involved in IL-37 signaling, being therefore 
relevant in different inflammatory contexts (listed in the figure). 
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2.2 Natural Killer cells 
2.2.1 NK cell definition: a historical perspective 
 
Natural Killer (NK) cells were originally described in 1975 independently by Kiessling and 
Herberman as lymphoid cells, “spontaneously” able to recognize and kill cancer and viral 
infected cells [93-96]. The first observation revealing the existence of this immune population 
was attempted in 1971, when Thornthwaite J.T. observed a particular murine cell type, first 
named CIPFC (Complement Independent Plaque Forming Cells) that was able to release a 
lytic agent and destroy the surrounding Sheep Red Blood Cells (SRBC), without any prior 
immunization [97, 98]. In 1975, these cells were called Natural Killer Cells and their capacity 
to destroy cancer cells was discovered. In particular, it was observed that the incubation of 
NK cells with a mastocytoma cell line (P815) caused the death of the tumor cells, occurring 
within minutes. They were defined as a “population of naturally occurring killer lymphocytes 
with specificity for tumor cells”. The term “natural” was used to underlie the spontaneous 
capacity of these cells to destroy target cells, differently from T cells, whose killing 
mechanism is antigen specific and MHC-restricted [99].  
The acquisition of cytotoxic activity has been evolutionarily associated with a robust and tight 
regulation to control the cytolytic process and reduce tissue damage. In this regard, the NK 
cell activation mechanism was deeply investigated over the last twenty-five years and it was 
shown to be dependent on the concept of a dynamic equilibrium [100]. Indeed, NK cells are 
able to recognize their target cells through a complex integration of antagonistic pathways 
downstream of activating and inhibitory receptors, whose engagement results in the 
regulation of cell effector functions. This mechanism dictates whether or not NK cells should 
be activated to kill the target cell and is also responsible for the discrimination between 
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healthy self-cells and target cells, thus avoiding the destruction of healthy self-components 
[101, 102]. A very sophisticated “zipper” is generated between NK cells and their partner 
cells, defining their synaptic contact, and the integration of activating and inhibitory signals 
governs NK cell function [103]. 
Since 2009, novel subsets of the innate lymphoid lineage have been identified and 
characterized and a recent nomenclature has proposed to call the innate lymphocytes, 
including NK cells, “Innate lymphoid cells” (ILCs) [104]. ILCs were defined by Spits H. in 
2012 as cells with “three main features: the absence of recombination activating gene (RAG)-
dependent rearranged antigen receptors; a lack of myeloid cell and dendritic cell phenotypical 
markers; and their lymphoid morphology” [104]. ILCs are divided in two lineages: cytotoxic 
ILCs that consist of conventional NK cells and 3 subsets of helper-like ILCs (ILC1, ILC2 and 
ILC3), which mirror the T helper cell profiles [105]. The subset identification was based on 
genetic reporter systems and it was defined as follows: cNK (IL-7Rα-, GATA-3 independent, 
Eomes+); ILC1 (IL-7Rα+, GATA-3 dependent, T-bet+); ILC2 (IL-7Rα+, GATA-3 dependent, 
GATA-3+); ILC3 (IL-7Rα+, GATA-3 dependent, ROR-γt/T-bet+). Recent studies have 
revealed transcriptional and functional plasticity among certain ILC subsets [105, 106]. 
Smyth’s group has recently shown that tumor infiltrating cNK cells (CD49a-CD49b+Eomes+) 
can be converted into “intermediate ILC1” (CD49a+CD49b+Eomes+) and ILC1 
(CD49a+CD49b-Eomes-) and this mechanism is driven by TGFβ signaling [107]. The 
localization, definition and role of ILC subsets in physiological or pathological conditions 
need to be further characterized. 
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2.2.2 NK cell development in mice and humans 
 
Multiparameter immunophenotyping, purification of specific cell subsets, in vitro 
differentiation systems and gene-modified/-reporter mouse models have played a key role in 
the characterization of the NK cell development process [108]. Di Santo’s and Caligiuri’s 
groups conducted pioneering studies to define the NK cell developmental pathway in mice 
and humans, respectively (Figure 5) [108, 109]. Both murine and human NK cell 
differentiation was conventionally divided into stages, although they obviously represent a 
simplification of a continuous process occurring from hematopoietic stem cells (HSC) to 
generate mature NK cells. As a result of pluripotency loss in HSC, NK cell committed 
precursors (NKP) are generated in the bone marrow and fetal thymus and they will give rise 
to mature NK cells, whereas other lineage options will be no longer available [110, 111].  
 
NK cell commitment 
In mice, NK cell committed precursors arise in the bone marrow from lymphoid progenitors, 
which are able to generate B, T and NK cells in vitro or upon transplant and are defined as 
early lymphoid progenitors (ELP; Lin-cKit+Flt3+) and common lymphoid progenitors (CLP; 
Lin-cKitlowIL-7RαlowSca-1lowFlt3low) [112-114]. It is not clear whether the transit through 
these intermediate subsets is really necessary for NK cells to develop and mature, since c-Kit-
deficient mice, which lack a fundamental molecule for stem cell differentiation, show normal 
numbers of NKP and mature NK cells [115]. Moreover, it was observed that the thymocyte 
precursor (CD44+CD25+) displays NK cell potential under certain conditions and even 
following Notch signaling, which is essential for T cell development [108, 116].  
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Figure 5. NK cell development. 
NK cell precursors and the major markers used to identify them in human and mice are shown (HSC: 
hematopoietic stem cells; CLP: common lymphoid precursors; pro-NK: NK progenitor; pre-NK or NKP: NK 
precursor; iNK: immature NK). The main transcription factors involved in early and late NK cell development 
are: Ets1, Id2, Pu.1, Ikaros, Tbet, Eomes and E4bp4. During the differentiation process NK cell loose the 
proliferative capacity and acquire a cytotoxic and cytokine producing potential. 
 
NK cell commitment appears to be dependent on CD122 (IL-2Rβ) expression, allowing IL-15 
responsiveness and indeed, NKP are defined as Lin-CD122+NK1.1-DX5- [117]. Interestingly, 
the differentiation of NKP from HSC is not dependent on IL-15, but it relies on other 
molecular signals that regulate CD122 expression, which are not fully characterized (they 
could include IL-7, Flt3L, c-KitL, IL-21) [118-120]. NKP were shown to have the potential to 
generate mature NK cells with a frequency of one in eight, in vitro [117]. 
In humans, NK cell differentiation studies were mainly performed as ex vivo analyses of 
CD34+ populations and collectively led to the proposal of a sequential model of early NK cell 
development, based on the surface expression of CD34, c-Kit, CD94 and CD16 [101, 109]. In 
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particular, the IL-15-non-responsive NK cell progenitor (pro-NK; CD34+, CD122-, 
CD45RA+, CD117- CD10+, 2B4+) gives rise to the IL-15-responsive NK precursor (pre-NK; 
CD34+, CD122+), following stimulation with IL-3, IL-7 and Flt3L, with a frequency of 1 in 
3.5 [121, 122]. Pre-NK cells give rise to immature NK (iNK) cells that are committed to the 
NK cell lineage. Indeed, they lack the expression of antigens associated with T, B and 
dendritic cells and they express NK-associated markers such as 2B4 and NKp44. However, 
they do not have the ability to produce IFN-γ and to mediate cytotoxicity [122]. 
The upstream signals regulating the transition from HSC to NK committed cells are still 
poorly understood but specific transcription factors are involved and cell-to-cell interaction 
are needed [108]. Indeed, HSC in liquid culture generate few NK cells, which are enriched in 
presence of stromal cells. Regarding transcriptional regulation, PU.1 was shown to act at 
early stages of NK cell development and a sophisticated balance of Id and E-box transcription 
factors (e.g. Id2 and E2A) determines NK cell fate [123, 124]. Ets-1 and Ikaros were also 
demonstrated to be critical for NK cell development, but their exact stage-specificity and 
mechanism of action have not been reported yet [125, 126].  
 
From NKP to mature NK cells 
NK committed precursors will then acquire the phonotypical and functional features of 
differentiated NK cells. In the mouse, Di Santo JP and Vosshenrich CA recently proposed the 
definition of immature and mature NK cells, derived from NKP, based on the acquisition of 
CD49b (DX5) [108]. The generation of immature NK cells (iNK; NK1.1+, DX5-) from NKP 
in the bone marrow is regulated by the T box transcription factor (Tbx21, encoding T-bet) and 
possibly the Nuclear factor interleukin-3-regulated protein (Nfil3 or E4bp4) [127, 128]. 
Mature NK cells (mNK) express DX5 and the transcription factor essential for this terminal 
step appears to be Eomes [129, 130]. Differentiated NK can be further subdivided in 4-stages 
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of maturation, based on the expression intensity of CD27, a member of the TNF receptor 
superfamily, and CD11b: double-negative (DN; CD27-CD11b-), CD11blow (CD27+CD11b-), 
double-positive (DP; CD27+CD11b+) and CD27low (CD11b+CD27-). These subsets were 
shown to be developmentally related and the transit from DN to CD11blow cells is considered 
the terminal maturation process of NK cells, which involves a decreasing proliferative 
capacity and increasing cytotoxic activity (Figure 6) [131].  
In humans, iNK cells differentiate towards mature NK cells, acquiring CD94-NKG2A, 
NKG2D and NKp46 expression, and the capacity to produce IFN-γ and kill [122, 132-134]. 
Mature NK cells are defined by the expression of the lineage marker CD56 and Lanier L. first 
proposed that CD56bright  (CD16+/-CD94+) and CD56dim (CD16+CD94-) NK cells represent two 
sequential stages of NK cell maturation [135]. In vitro and in vivo evidences largely 
supported this hypothesis and indeed, CD56bright NK cells express c-Kit and are poorly 
cytotoxic. Following stem cell in vitro differentiation or in vivo transplantation CD56bright NK 
cells appear earlier than CD56dim NK cells [136-138]. It was observed that T-bet mRNA 
expression, which is crucial for murine NK cell development, is induced in human CD56+ NK 
cells (Figure 6) [139].  
 
 
 
36 
 
 
Figure 6. Mature human and murine NK cell subsets. 
Mature NK cell subesets and the major markers used to identify them in human and mice are shown. During the 
late differentiation process NK cell loose the proliferative and cytokine producing capacity and acquire a 
cytotoxic potential. 
 
2.2.3 NK cell localization and organ-specific features of NK cells 
 
NK cell maturation drives the acquisition of several chemotactic receptors and adhesion 
molecules, allowing NK cells to migrate from the bone marrow through the blood to spleen, 
liver, lung, lymph nodes, omentum and uterus during gestation [140, 141]. It is generally 
accepted that early steps in NK cell development occur within the bone marrow but it is 
unclear whether final maturation could also be completed in other organs. In this regard, the 
identification of NK cell precursors in human lymph nodes and immature TRAIL+ NK cells in 
murine liver and spleen could support this possibility [142].  
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NK cells represent a minor fraction of lymphocytes in most tissues (e.g. in the mouse: 2-3% 
in spleen, 3-4% in peripheral blood, 0,5-1,5% in bone marrow, 10% in lung and 8-10% in 
liver; in humans: 2-18% in peripheral blood and 30-50% in liver) [141]. NK cell turnover was 
shown to be around two weeks in blood, both in mice and humans [143]. 
 
Figure 7. NK cell localization. 
BM-derived NK cells exert the bone marrow, circulate through the blood and reach several organs in 
physiological and pathological conditions. Their migration and localization to different districts is driven by 
different chemokines-chemokine receptors (indicated in the figure). 
 
NK cells subsets, which are functionally diverse, display distinct homing capacity and 
localization and therefore organ-specificity. Indeed, in the mouse, immature NK cells 
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cells (CD11b+CD27low) are largely present in blood, spleen, liver and lung. The intermediate 
population (CD11b+CD27+) is homogenously distributed [144]. Moreover, a subset of B220+ 
CD11c+ NK cells was described as enriched in secondary lymphoid structures and it is able to 
secrete high levels of IFNγ [145]. In humans, the majority of circulating and splenic NK cells 
displays a mature and potentially active phenotype (CD56dimCD16+Perforin+). 
CD56brightCD16- NK cells are considered an earlier stage of NK cell maturation and are 
predominantly found in tonsils and lymph nodes and produce cytokines (IFNγ, TNFα and 
GM-CSF) after stimulation with pro-inflammatory factors [146]. Immature NK cells do not 
express cytoplasmic perforin and they acquire cytotoxic capacity only after sustained and 
prolonged stimulation. Murine NK cells lack the expression of CD56, making it difficult to 
compare murine and human NK cells. Nevertheless, there is evidence that immature NK cells 
in the mouse resemble CD56high human NK cells [103]. 
 
Hepatic NK cells 
The liver represents a unique immunological landscape, enriched in NK cells, which are 
preferentially located in the sinusoids and often adhere to endothelial cells [147]. NK cells 
represent 5-10% and 30-50% of hepatic lymphocytes in mice and humans, respectively and 
certain pathological conditions, such as viral infections, drive a profound accumulation of NK 
cells in the liver [140, 148]. Hepatic NK cells show distinct phenotypic features compared to 
mature NK cells and several lines of evidence have suggested that liver NK cells and 
conventional NK cells arise from different precursors. For instance murine hepatic NK cells 
express lower levels of maturation markers, such as CD11b, KLRG1 and Ly49 receptors, and 
higher levels of the apoptosis inducers TNF-related apoptosis-inducing ligand (TRAIL) and 
FasL. Liver-resident cells produce CCL2, CCL3, CXCL10 and CXCL16 and therefore 
mediate the recruitment of NK cells expressing CCR1, CCR2, CCR3, CCR5, CXCR3 and 
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CXCR6 [149, 150]. The specific features of liver-resident NK cells reflect their ability to 
adapt to specific environments and in support of this, it was shown that adoptively transferred 
splenic NK cells can migrate to the liver and adopt phenotypic and functional features closely 
similar to liver resident NK cells [151].  
Hepatic NK cells face the task of balancing the immune response against viruses, bacteria, 
stressed or transformed cells and tolerance to food, self antigens and gut-derived microbiota 
antigens. At steady-state condition, NK cells promote liver tolerance [147]. Indeed, it was 
shown that liver NK cells express high levels of the inhibitory receptor NKG2A, compared to 
systemic NK cells. LPS and (lipoteichoic acid) LTA that arrive in the liver activate Kupffer 
cells, triggering the release of IL-10 and the induction of NKG2A in NK cells, which may 
contribute to NK cell-mediated liver tolerance. NKG2A engagement in hepatic NK cells is 
indeed responsible for the promotion of a tolerogenic phenotype of dendritic cells [140, 152].  
In the inflamed liver, IFNα, IFNγ, IL-2, IL-6, IL-12, IL-15 and IL-18, produced by Kupffer 
cells, NKT cells and other liver resident cells, contribute to the activated phenotype of NK 
cells [152]. Hepatic NK cells are crucial mediators of the innate resistance to several hepatic 
viruses, such as hepatitis B and C virus (HBV and HCV), which is favored by liver-resident 
specific features of NK cells. Viral PAMPs activate Kupffer cells, which produce IL-6 and 
IL-18 and in turn trigger the activation of NK cells, boosting their killing capacity. In hepatic 
NK cells, increased expression of NKp30 was shown to promote the control of HBV and 
IFNα-induced expression of TRAIL might be associated with HCV clearance. In this regard, 
liver NK cells play a key role in the therapeutic activity of IFNα treatment in HBV and HCV 
patients [153-155]. Following viral infection, hepatic NK cells can acquire a memory 
phenotype, retaining antigen-specific memory in the absence of viral persistence, which 
depends on CXCR6 expression [154]. 
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Figure 8. Hepatic NK cells.  
NK cells migrate and then reside in the liver through different chemokine receptors (CCR2, CCR1, CXCR3) and 
S1PR. The liver is particularly enriched with NK cells, which display a peculiar liver-specific phenotype: they 
express high levels of NKG2A, TRAIL and FasL. Kupffer cells produce high levels of IL-18, which induces NK 
cell activation. 
 
In chronic liver disease, NK cells have been suggested to favor tissue damage and viral 
persistence and inhibit liver fibrosis and tissue regeneration mediated by pericytes (hepatic 
stellate cells; HSC). Indeed, activated NK cells can kill hepatocytes and hepatic stellate cells, 
resulting in liver injury and wound-healing inhibition [140, 156]. These mechanisms were 
demonstrated to be dependent on TRAIL- and NKG2D-dependent activation of NK cells. In 
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chronic HBV- and HCV- infected patients, NKG2Ahigh phenotype of NK cells might 
contribute to facilitate viral persistence [157, 158].  
Thus, in physiological conditions, hepatic NK cells are involved in liver tolerance and 
comprise a memory-like population. In acute viral infection, chemokines produced by liver-
resident cells drive the further accumulation of NK cells, which contribute to viral control and 
clearance. Liver NK cell cytotoxicity is strictly regulated to maintain tolerance at steady-state 
conditions and avoid bystander tissue damage after viral clearance. However, in chronic 
stages of liver infection, NK cells favor liver injury and pathogen persistence and inhibit liver 
fibrosis and tissue remodeling.  
 
NK cells in other organs 
In mucosal tissues, the difficulty of the discrimination of bona fide conventional NK cells and 
non NK cell-ILCs has been a major challenge and the role of this cell types in physiological 
and pathological conditions need to be further elucidated. Nevertheless, NK cells represent 
10% of lymphocytes in the healthy lung and are also present in skin and gut.  
Lung NK cell progenitors were shown to differ compared to bone marrow NK cell precursors 
and mature lung NK cells express various LY49 receptors and produce higher amounts of 
TNF, in case of S.aureus infection. During acute lung infections, NK cells are enriched in the 
broncho-alveolar space and their recruitment is mediated by CCR2, CXCR3 and CX3CR1 
[159]. 
In skin lesions of psoriatic patients, NK cells are localized in the mid and papillary dermis, 
account for 5-8% of total infiltrating cells and their homing in the skin is dependent on 
keratinocyte-derived CCL5 and CXCL10. NK cells in the skin exhibit a CD56brightCD158b- 
phenotype and secrete high levels of IFNγ [160].  
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In the intestine, NK cells are located predominantly within the lamina propria and are thought 
to be involved in the protection against viruses and intracellular pathogens. In humans, a 
cytotoxic, IFNγ-producing, NKp44+CD103+CD56+CD3- population has been identified in the 
oral and intestinal mucosa, located within the epithelium [161]. Recently, the characterization 
of NKp46+RORγt+ ILCs and their plasticity towards NKp46+RORγt- cells has increased the 
complexity in the discrimination of intestinal cNK cells and ILCs [162]. Further studies are 
required to elucidate their phenotypic features and role in gut homeostasis and inflammation 
[163].  
NK cells are present in non-pregnant uterus and abundantly accumulate in the decidua during 
pregnancy. Uterine NK cells represent 70% of decidual leukocytes in early pregnancy and 
exhibit a unique phenotype [164, 165]. They are CD56brightCD16-, they are poorly cytotoxic 
but contain cytoplasmic granules and they express higher levels of KIRs and CD94/NKG2 
receptors, which recognize HLA-C and HLA-E on trophoblast, respectively [166-168]. 
During pregnancy, they play a crucial role in arterial remodeling, produce angiogenic factors 
(e.g. VEGF and PLGF) and induce Treg cells, contributing to the maternal-fetal tolerance 
[169, 170]. 
In the central nervous system, there is no evidence on the presence of NK cells in 
physiological conditions and the integrity of the blood-brain barrier and epithelial blood-
cerebrospinal fluid barrier prevents the influx of immune cells [171]. However, NK cells have 
been detected in the inflamed CNS during infections [172, 173], in glioma-bearing mice, in 
which NK cells account for the 50% of all CNS leukocytes, and in EAE models [174, 175]. 
NK cell recruitment in the CNS depends on CX3CL1 secreted by neurons and CCL2 and 
CXCL10 produced by microglia, astrocytes and other inflammatory cells [176, 177]. NK cells 
within the brain play a protective role during viral infections and chronic inflammatory 
conditions, in which they may have an anti-inflammatory role. In this regard, it was shown 
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that CNS NK cells express high levels of the inhibitory receptor NKG2A and can directly lyse 
microglia, thus inhibiting the activation of autoimmune T cells [176, 177]. In the murine EAE 
model, NK cells negatively regulate CNS inflammation and depletion of NK cells is 
associated with exacerbated neurological defects [178, 179]. 
2.2.4 Regulation of NK cell functions 
 
NK cell activation depends on a delicate balance between activating and inhibitory signals 
and the integration of these pathways prevents NK self-reactivity and governs NK cell 
activation in presence of cells in “distress” (Table 1, Figure 9) [100, 103]. NK cells, once 
activated, can be actively cytotoxic through the release of perforin and granzymes and can 
secrete cytokines, such as IFNγ, thus participating in the shaping of the adaptive immune 
response [103, 180, 181]. NK cell effector functions also include antibody-dependent cell 
cytotoxicity (ADCC): NK cells recognize antibody-coated target cells through the FcγRIIIA 
(CD16), which is coupled to CD3ζ and FcRγ polypeptides, bearing the activatory domains 
ITAM (immunoreceptor tyrosine-based activation motif) [182] [100]. NK cells recognize 
damaged, stressed, infected or tumor cells, which express ligands interacting with activating 
NK cell receptors. Stress-induced ligands on host cells, such as human ULBP and MIC or 
mouse RAE1, H60 and MULT1 molecules can interact with the activating receptor NKG2D 
on NK cells [183]. Other ligands of activating receptors are viral encoded non self-ligands, 
which include cytomegalovirus-encoded m157, directly recognized by Ly49H in the mouse, 
and TLR ligands, even though the direct role of TLRs in NK cells remains an unsettled issue 
[184-187]. The natural cytotoxicity receptors (NCR), such as NKp46/NCR1, NKp44/NCR2 
and NKp30/NCR3, which are linked to ITAM-bearing CD3ζ, FcRγ or DAP12, are other 
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potent activating receptors. NKp46 was reported to interact with influenza- and parainfluenza-
derived hemagglutinins [188].  
  
NK	  cell	  receptors	  and	  ligands	  
Receptor	   Ligands	   Expression	  on	  other	  cells	  
Inhibitory	   Activating	  
KIR	  
(humans)	   MHC	  class	  I	  
Effector	  and/or	  
memory	  T	  cells	   X	   X	  
Ly49	  
(mouse)	   MHC	  class	  I	  
Effector	  and/or	  
memory	  T	  cells	   X	   X	  
NKG2A	   HLA-­‐E	  (humans)	  and	  Qa1	  (mouse)	   Effector	  and/or	  memory	  T	  cells	   X	   	  	  
NKG2C	   HLA-­‐E	  (humans)	  and	  Qa1	  (mouse)	   Effector	  and/or	  memory	  T	  cells	   	  	   X	  
NKG2D	  
MICA,	  MICB,	  ULBP1-­‐6	  (human)	  
and	  RAE1a-­‐e,	  H60a-­‐c,	  MULT-­‐1	  
(mouse)	  
T	  cells,	  activated	  
macrophages	   	  	   X	  
DNAM1	   PVRL2,	  PVR	   T	  cells	  and	  monocytrs	   	  	   X	  
TIGIT	   PVRL2,	  PVR	   T	  cells	   X	   	  	  
Tactile	   PVR	   T	  cells	   X	   	  	  
FcγRIIIA	   Fc	  domain	  of	  IgG	   Activated	  monocytes	  and	  macrophages	   	  	   X	  
NKp46	   HS,	  HN,	  HA,	  vimentin,	  PfEMP1,	  bacterial	  components	  	  
T	  cell	  subsets	  and	  
ILC3	   	  	   X	  
NKp44	  
HS,	  PCNA,	  KNp44L,	  HN,	  HA,	  viral	  
glycoproteins,	  bacterial	  
components	  
T	  cell	  subsets,	  ILC3,	  
pDCs	   	  	   X	  
NKp30	   B7-­‐H6,	  HS,	  BAt3,	  HA,	  HCMV	  pp65,	  PfEMP1	  
T	  cell	  subsets	  and	  
epithelial	  cells	   	  	   X	  
PD1	   PDL1,	  PDL2	  
Activated	  T	  and	  B	  
cells	  and	  myeloid	  
cells	  
X	   	  	  
4-­‐1BB	   4-­‐1BBL	   T	  cells,	  DCs	  and	  endothelial	  cells	   	  	   X	  
 
Table 1. NK cell receptors and ligands. 
NK cells receptors and their ligands expressed by other cell types are listed.  
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NK cell response also depends on the cytokine microenvironment and the interaction with 
other immune cells, such as dendritic cells, macrophages and T cells. IL-12, IL-18, IL-15 and 
type I IFN are strong activators of NK cell effector functions and IL-2 favors NK cell 
proliferation and activation. CD4 T cell mediated-production of IL-2 in lymph nodes, DC and 
macrophage-derived IL-18 and IL-15 activate NK cells, whereas T regulatory cell-derived 
TGFβ negatively regulates NK cell function. It has been appreciated that, despite their 
original definition of natural killers, NK cells do require “priming” to gain a full activation 
state. IL-15 and IL-18 are well-described mediators of NK cell priming in both steady state 
and inflammatory conditions [189-195].  
NK cell inhibitory receptors prevent NK cell autoreactivity while allowing recognition and 
killing of stressed target cells. NK cells express several MHC class I-specific inhibitory 
receptors that include the lectin-like Ly49 dimers in the mouse, the killer cell 
immunoglobulin-like receptors (KIRs) in humans and the CD94-NKG2A heterodimers in 
both species, all sharing the intra-cytoplasmic inhibitory domains ITIMs (immunoreceptor 
tyrosine-based inhibition motifs) [196, 197]. Other NK cell inhibitory receptors that do not 
recognize MHC class I molecules are 2B4 and NKR-P1A in the mouse and NKR-P1B in 
humans [102, 198]. NK cells can detect the lack of MHC class I occurring in viral infected or 
tumor cells and this process is called the “missing self” recognition. Thus, healthy cells that 
express MHC class I molecules and low levels of stress-induced molecules are protected from 
NK cell killing, whereas cells “in distress” that up-regulate stress-induced ligands and down-
regulate MHC class I molecules are recognized and killed [102, 199, 200].  
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Figure 9. Regulation of NK cell activation. 
NK cell activation is dependent on a delicate balance between activating and inhibitory receptors, which 
engagement drives NK cell inhibition and/or NK cell activation. Healthy cells express inhibitory ligands and do 
not activate NK cells. Target cells (e.g. tumor cells) can down-modulate inhibitory ligands and upregulate or de 
novo express activating ligands, therefore activating NK cell response. 
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 NK cell education 
The acquisition of NK cell tolerance to self depends on the expression of MHC class I 
specific-inhibitory receptors and on the “education” or “licensing” system. NK cell education 
occurs during NK cell development and is based on the need to avoid auto-reactivity, 
ensuring the generation of self-tolerant killer cells [201-203]. Since NK cell receptors do not 
undergo somatic recombination, their potential for autoreactivity is due to the fact that the 
expression pattern of MHC class I receptors is largely random. Some NK cells lack inhibitory 
receptors that recognize MHC class I and/or express activating receptors that recognize self 
ligands, including MHC molecules [196]. During the education process, NK cells that lack 
self MHC-specific inhibitory receptors become hyporesponsive, whereas NK cells that 
express MHC receptors are responsive to stimulation but tolerant to self cells, which indeed 
engage the MHC-specific inhibitory receptors. For instance, in mice or humans that lack 
MHC class I molecules, NK cells fail to kill MHC class-I deficient autologous cells and 
display reduced responses to other stimulations [204-206]. In humans, NK cells expressing 
the activating receptor KIR2DS1, which is specific for the HLA-C2, are responsive in HLA-
C1/C1 or HLA-C1/C2 donors, but not in HLA-C2 donors [207, 208]. The intensity and 
quality of NK cell response was shown to be commensurate with the number of different self-
MHC inhibitory receptors expressed by the cell. Whether the process of NK cell education 
depends on the active “arming” (e.g. the induction is mediated by MHC-specific inhibitory 
receptors) or the active “disarming” (e.g. the induction is mediated by the lack of MHC-
specific inhibitory receptors), or both, is still matter of debate [209].   
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2.2.5 Tumor surveillance mediated by NK cells 
NK cells were first reported to be implicated in tumor surveillance around 1980, when 
defective NK cell function caused by genetic disorders was correlated with a higher incidence 
of cancer in humans [210]. In agreement, mutant mice with impaired NK cell function or 
treated with NK cell-depleting antibodies showed increased tumor growth and metastasis 
[211, 212]. Later, a seminal long-term epidemiological study demonstrated that the 
susceptibility to various types of cancer increased in patients with impaired NK cell activity 
[213]. Moreover, NK cell deficiencies in humans correlated with higher rates of malignancy 
and NK cell function was found to be impaired in cancer patients [214].  
However, the reported immunodeficiencies and genetic defects affect other immune cell types 
in addition to NK cells and the ablation of NK cells in the mouse is not 100% specific. Even 
though NK cells are able to kill a variety of tumor cell lines in vitro, the real contribution of 
NK cells in primary solid tumors in physiological settings still remains to be clarified. The 
importance of NK cell-mediated killing of nascent tumors may be speculated, although it is 
very difficult to have a formal demonstration of this concept.  The current literature suggests 
that NK cells play a crucial role in the prevention and control of hematological malignancies 
and metastases, but to what extent they are involved in the control of primary tumor growth is 
matter of debate, also considering the fact that NK cells represent a minor fraction of the 
tumor immune infiltrate and have limited prognostic significance compared to other 
lymphocytes, such as CD8+ T cells and T regulatory cells [215, 216]. 
 
The interplay between NK cells and tumors 
NK cell recognition of transformed cells is based on the altered balance of activating and 
inhibitory ligands expressed by target cells. NK cell killing activity can be activated by tumor 
cells that down-regulate MHC class I molecules, possibly because of a selective pressure 
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mediated by CD8+ T cells. Alternatively, NK cells can recognize and eliminate tumors that 
retain MHC class I expression and express one or several activating ligands, thus overcoming 
the inhibitory signals [215]. The best characterized ligands expressed on tumor cells able to 
trigger NK cell activation are the NKG2D and NCR ligands [188, 217]. Indeed, NKG2D-
deficient (Klrk1-/-) mice are more susceptible to the development of several types of primary 
tumors, such as transgene-driven lymphoma and prostate carcinoma and the overexpression of 
NKG2D ligands is protective in models of transplanted tumors [218-220]. The contribution of 
NCR signaling in NK cell-mediated control of tumors was assessed by in vitro cytotoxicity 
assays, in which neutralizing monoclonal antibodies against NCRs blocked the killing 
capacity of NK cells [188]. Moreover, Nkp46-deficient (Ncr1-/-) mice were shown to be more 
sensitive in transplantable models of lymphoma, Lewis lung carcinoma, B16 melanoma 
metastasis and glioblastoma [221-223]. Several ligands expressed by tumors have been 
proposed to engage the NCRs, including heparan sulfates, but the only validated ligand is B7-
H6, which binds Nkp30 and is expressed by leukemias, lymphomas, melanomas and 
carcinomas [224].  
In the model of methylcholanthrene (MCA)-induced sarcoma, Klrk1-/- and Ncr1-/- mice do not 
exhibit any enhanced susceptibility, but NK cell depletion experiments demonstrated a crucial 
role of NK cells in the tumor control [220, 225]. Indeed, a higher incidence of tumor 
development was observed in RAG-IL-2rγc-deficient (Rag2-/-Il2rg-/-) mice, which in addition 
to B and T lymphocytes lack NK cells, compared to RAG-deficient (Rag2-/-) mice [226]. The 
NK cell-mediated control of MCA-derived sarcomas was demonstrated to be dependent on 
IFNγ production`, together with the consequent macrophage polarization and activation. 
Moreover`, MCA-induced tumors arising in the absence of NK cells were shown to be more 
immunogenic when transplanted in wild-type hosts`, suggesting an NK-based immunoediting 
process [226]. In agreement, MCA-driven sarcomas and DMBA-driven papillomas developed 
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in DNAM1-deficient (Cd226-/-) mice expressed higher levels of the DNAM1 ligand CD155. 
Evidence for NKG2D-mediated editing was observed in MCA-sarcomas derived from Prf-/- 
mice and Myc-driven B cell tumors derived from Klrk1-/- mice [142, 220, 227]. Similarly, 
higher levels of NKp46 ligands, detected with an NKp46-Ig fusion protein, were observed in 
sarcomas isolated from Ncr1-/- mice [225].  
Even though these results suggest a role of NK cells in primary tumor surveillance and tumor 
immune-editing, which is primarily mediated by adaptive immune cells, the specific 
contribution of NK cells still needs to be elucidated, since DNAM1, NKG2D and NCRs are 
also expressed by subsets of NKT, T cells and ILCs. For instance, it was recently shown that 
NKGD2-deficient mice are more susceptible to the development of diethylnitrosamine 
(DEN)-induced hepatocellular carcinoma and the major role in tumor control was played by 
NKG2D+ T cells [228].   
Tumors have developed strategies to evade the immune response and several mechanisms that 
enable tumor cells to escape the NK cell-mediated control have been documented. For 
example, it was shown that tumors can shed the NKG2D ligands to decrease NK cell 
activation and soluble NKG2DLs were detected in sera of cancer patients, suggesting the 
potential role of NKG2DLs as diagnostic markers [229-232]. Moreover, soluble factors 
produced by tumor cells, such as lactate dehydrogenase, induce the expression of NKG2DLs 
on host myeloid cells [233]. Recently, it was demonstrated that the treatment of tumor-
bearing mice with a recombinant high-affinity NKG2DL (MULT-1) could reverse the de-
sensitization of NK cells driven by NKG2DL cleavage and NKG2D engagement by host cells 
[234]. Other escape mechanisms established by tumors cells are the activation of platelets, 
which inhibits NK cells, the expression of inhibitory ligands and the production of factors that 
suppress NK cell maturation and activation, such as TGFβ, prostaglandin E2 (PGE2), 
indoleamine 2,3-dioxygenase (IDO), adenosine and IL-10 [235-239].   
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NK cell subsets in solid tumors and hematological malignancies 
Tumorigenesis significantly alters the distribution and functionality of NK cell subsets, which 
are characterized by extensive heterogeneity and plasticity and may play specific distinct roles 
during cancer progression [240-242]. Poorly cytotoxic CD56highCD16- NK cells were shown 
to be the prevalent tumor-infiltrating NK cell subset within different solid tumors, such as 
breast, melanoma, colon cancer and non-small lung cancer [243, 244]. Unlike peripheral 
blood CD56highCD16- NK cells, tumor infiltrating NK cells (TINK) express high levels of 
CD9, CXCR3, have lower cytotoxic capacity and produce VEGF, displaying a tumor-
promoting, pro-angiogenic phenotype, similarly to decidual NK cells (dNK) [169, 242]. In 
breast and lung cancer, the accumulation of poorly cytotoxic CD56highperforinlow NK cells 
was described to be due to a peculiar chemokine milieu within the tumor stromal 
compartment. Indeed, it was observed an up-regulation of CXCL9 and CXCL10, which 
recruit CD56high NK cells and a down-regulation of CXCL2, which attracts CD56dim NK cells. 
In breast cancer patients, a higher frequency of immature and less functional NK cells (CD16-
CD117highCD27highCD57low) was found in both peripheral blood and advanced mammary 
tumors. Moreover, NK cell activating receptor expression can be also impaired in cancer 
patients, favoring the suppression of NK cell activation [245, 246]. For instance, in prostate 
cancer patients, NK cells exhibited a lower expression of several activating receptors (e.g. 
NKp46, NKp30, NKG2D, DNAM1 and CD16) and a higher expression of the inhibitory 
receptor ILT2, with more pronounced alterations in NK cells infiltrating metastases than 
primary lesions [247].  
Impaired NK cell function was also described in acute and chronic leukemia (acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic 
leukemia (CLL), chronic myeloid leukemia (CML)), myelodysplastic syndromes (MDS) and 
multiple myeloma. In AML patients, an enrichment of NCRlowCD16+KIR+ NK cells, which 
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failed to recognize autologous and allogeneic blasts, was described [248, 249]. In AML and 
ALL patients, peripheral blood NK cells express lower levels of NKp46 and higher levels of 
NKG2A and in MDS, AML and MM patients, a lower frequency of NKG2D+ and DNAM1+ 
NK cells was observed. [250, 251] Recently, it was described a novel 
CD56lowCD16lowNKG2A+ NK cell subset in pediatric ALL patients. In healthy donors, this 
subset was shown to be highly cytotoxic and produce high levels of IFNγ, whereas in 
leukemic patients it was shown to be functionally impaired [252]. Finally, in the context of 
CLL and CML, the frequency and the receptor profile of CD56low NK cells were similar to 
those in healthy donors, but they showed reduced cytotoxic capacity [253].  
Collectively, these data demonstrate that several mechanisms, including direct suppression of 
NK cell activation, modulation of NK cell receptors, NK cell maturation and localization are 
responsible for NK cell functional impairment in solid tumors and hematological 
malignancies.  
 
NK cell anti-metastatic activity 
Although the role of NK cells in the protection against primary solid tumors is still debated 
and controversial, NK cells are credited to play a prominent role in the control of the 
metastatic spread, which is a leading cause of cancer-related death [254]. Indeed, in several 
types of cancer (e.g. gastrointestinal sarcoma, gastric, colorectal, renal and prostate 
carcinoma) the frequency of circulating or infiltrating NK cells inversely correlated with the 
presence of metastases [255]. In agreement, NK cell cytotoxic capacity or NK cell activating 
receptor expression was associated with good prognosis in multiple cohorts of cancer patients 
with or at risk of metastases. For example, prostate cancer patients who showed the 
infiltration of NKG2DhighNKp46high NK cells did not develop metastases after surgery, with a 
follow-up of one year [256]. In several preclinical models, NK cell impairment or depletion 
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was associated with increased metastatic spread, whereas no difference was observed in 
primary tumor growth, in mice inoculated with syngeneic cancer cell lines, via the 
intravenous, intracardiac, subcutaneous, intrasplenic or orthotopic route [218, 257, 258]. 
Along the same line, treatments that boost NK cell activation were demonstrated to provide 
protection in murine models of metastases [259-261].  
The mechanisms of NK cell elimination of metastases and reasons for the more efficient 
control of metastases compared to primary tumors are not fully elucidated. It is known that 
epithelial to mesenchymal transition (EMT) is associated with the upregulation of NKG2D 
ligands (MICA, MICB and ULBPs) and the loss of inhibitory ligands. For instance, the down-
regulation of the KLRG1 ligand E-cadherin, which is a hallmark of EMT, allowing epithelial 
cells to reduce adhesion and increase motility, renders the tumor cells more susceptible to NK 
cell killing [262, 263]. Secondly, trafficking and organ-specific enrichment of NK cells is a 
major determinant in their antimetastatic capacity [254, 264]. At which step or steps of the 
metastatic cascade NK cells act is still controversial. Indeed, most metastasis models are 
based on transplanted tumors, which do not recapitulate the early metastatic process and rely 
on late timepoints, being therefore unable to dissect the contribution of NK cells in the control 
of each step. In this regard, whether NK cell activity is determinant in the local dissemination, 
hematogenous spread or tumor growth in the colonized site remains an open issue. On the 
other hand, the role of NK cells in controlling solid tumors may have been actually 
underestimated because of the difficulty in setting up models to monitor the early stages of 
carcinogenesis.  
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2.2.6 NK cell-based immunotherapy 
 
Targeting NK cells, or the immunosuppressive microenvironment to restore or boost NK cell 
activity is a promising therapeutic tool and several clinical trials have been recently developed 
to address this issue. The growing number of studies elucidating the molecular mechanisms of 
NK cell activation and inhibition, their interplay with tumor cells and their homing within the 
tumor microenvironment have provided the basis for the establishment of novel encouraging 
strategies to enhance NK cell antitumor immunity in the clinic (Table 2) [265].  
 
Adoptive NK cell therapy 
The first NK cell therapy was reported around 1980 and regarded the infusion of IL-2 
activated NK cells, called lymphokine-activated killer (LAK) cells, in cancer patients [210]. 
This approach was limited by the toxicity of IL-2, partially due to the expansion of Treg cells, 
which were discovered later.  In 2002, Velardi and colleagues observed that AML patients 
who underwent allogeneic bone marrow transplantation with a KIR/HLA-C mismatch 
showed relapsed at a lower rate, which was the first clinical evidence of an NK cell-mediated 
benefit in therapy [266]. In this setting, alloreactive NK cells can efficiently eliminate tumor 
cells, which lack the proper MHC class I ligands engaged by KIRs, suggesting that NK cells 
mediate an alloresponse towards AML blasts, without causing graft-versus-host-disease 
(GVHD) [266].  
 
Therapeutical	  approaches	  to	  target	  NK	  cells	  
Therapy	   Stage	   Advantages	   Drawbacks	   Trial	  
Adoptive	  
transfer	  
Autologous	  
NK	  cells	  
Clinical	  trial	  
(or	  FDA	  
Safe	   Low	  efficacy	  
UMIN00000752
7	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approved	  if	  
part	  of	  
HSCT)	  
	  	  
Allogeneic	  
NK	  cells	  
Clinical	  trial	  
(or	  FDA	  
approved	  if	  
part	  of	  
HSCT)	  
Highly	  effective	  in	  
some	  malignancies	  
in	  case	  of	  KIR-­‐
mismatch	  
Substantial	  
depletion	  of	  T	  
cells	  needed	  to	  
avoid	  GVHD	  
NCT00187096	  
	  	   NK	  cell	  lines	   Clinical	  trials	  
Easy	  to	  expand,	  
safe	  transfer	  after	  
irradiation	  
Low	  efficacy	  if	  not	  
modified	  
NCT00900809;	  
NCT02465957	  
	  	   CAR	  NK	  cells	   Clinical	  trials	  
Redirect	  NK	  cell	  
activity	  against	  a	  
specific	  tumor	  
antigen	  
Difficulty	  to	  
manufacture	  
NCT0099513;	  
NCT01974479	  
Cytokines	   IL-­‐2	  
FDA	  
approved	  
Repeated	  
injections	  well	  
tolerated	  at	  low	  
doses	  
Toxicity	  at	  high	  
doses	  (capillary	  
leak	  syndrome,	  
activation	  of	  
Tregs)	  
	  	  
	  	   IL-­‐15	   Clinical	  trials	  
Activates	  both	  NK	  
cells	  and	  CD8	  T	  
cells,	  no	  activation	  
of	  Tregs	  	  
Potential	  toxicity	  
(fever,	  
thrombocytopeni
a	  and	  
hypotension)	  
NCT01385423;	  
NCT01875601	  
	  	  
ALT-­‐803	  (IL-­‐
15SA-­‐IL-­‐
15Ra-­‐Su-­‐Fc)	  
Clinical	  trial	  
More	  potent	  NK	  
cell	  activator	  than	  
IL-­‐15	  
Potential	  toxicity	   NCT02099539	  
Anti-­‐cancer	  
agents	  
IMiDs	  and	  
imatinib	  
mesylate	  
FDA	  
approved	  
Direct	  anti-­‐tumor	  
effect	  combined	  
with	  
immunostimulator
y	  effects	  
	  	   	  	  
	  	  
Bortezomib	  
and	  
genotoxic	  
agents	  
FDA	  
approved	  
Direct	  cytotoxicity	  
toward	  tumor	  
cells,	  sensitize	  
tumor	  cell	  to	  NK	  
cell	  killing	  
Might	  have	  
suppressive	  
effects	  
	  	  
	  	  
GSK3	  
inhibitors	  
Clinical	  trial	  
Direct	  anti-­‐tumor	  
effect,	  enhances	  
NK	  cell	  killing	  
Might	  promote	  
Treg	  cell	  function	  
NCT01632306;	  
NCT01287520;	  
NCT01214603	  
Targeting	  
immune	  
suppression	  
Depletion	  of	  
Treg	  cells	  	  
Clinical	  trial	  
Improves	  efficacy	  
of	  haploidentical	  
NK	  cell	  transfer	  
	  	   NCT01106950	  
	  	  
Inhibitors	  of	  
the	  TGF-­‐β	  
Clinical	  trial	  
and	  FDA	  
approved	  
Broad	  effect	  on	  
immune	  responses	  
not	  restricted	  to	  
Effects	  of	  TGF-­‐β	  
blockade	  on	  
tumor	  
NCT02304419	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pathway	   (not	  for	  
cancer)	  
NK	  cells	   progression	  not	  
well	  defined	  
	  	  
Inhibitors	  of	  
the	  
adenosinergi
c	  pathway	  
Clinical	  trial	  
Safe,	  broad	  effect	  
on	  immune	  
responses	  not	  
restricted	  to	  NK	  
cells	  
	  	   NCT02403193	  
Agonists	  of	  NK	  
cell	  activating	  
receptors	  
Tumor-­‐
targeting	  
mAbs	  
FDA	  
approved	  
Redirect	  NK	  cell	  
activity	  against	  a	  
specific	  tumor	  
antigen	  
Possible	  on-­‐
target,	  off-­‐tumor	  
effect	  
	  	  
	  	  
BiKEs	  and	  
TriKEs	  
Pre-­‐clinical	  
developmen
t	  
Redirect	  NK	  cell	  
activity	  against	  a	  
specific	  tumor	  
antigen	  
Possible	  on-­‐
target,	  off-­‐tumor	  
effect	  
	  	  
	  	  
mAbs	  to	  
CD137	  
Clinical	  trial	  
Stimulate	  NK	  cell	  
ADCC	  and	  T	  cells	  
Conflicting	  
reports	  on	  the	  
stimulation	  of	  
human	  NK	  cells,	  
severe	  liver	  
toxicity	  at	  high	  
doses	  
NCT02420938;	  
NCR01775631;	  
NCT01307267;	  
NCT02110082	  
Checkpoint	  
inhibitors	  
mAbs	  to	  KIRs	  
(IPH2101	  and	  
IPH2102)	  
Clinical	  trials	  
Safe,	  KIR	  inhibition	  
(can	  be	  used	  in	  any	  
patient	  without	  KIR	  
genotyping)	  
Low	  efficacy,	  
needs	  
combination	  
NCT02399917;	  
NCT01592370;	  
NCT02252263;	  
NCT02599649;	  
NCT02481297;	  
NCT01687387;	  
NCT01714739;	  
NCT01750580	  
	  	  
mAbs	  to	  
NKG2A	  
(IPH2201)	  
Clinical	  trials	  
NKG2A	  inhibition	  
(can	  be	  used	  in	  any	  
patient	  without	  KIR	  
genotyping)	  
	  	  
NCT02459301;	  
NCT02331875;	  
NCT02557516;	  
NCT02643550;	  
NCT02671435	  
Table 2. Therapeutical approaches to target NK cells. 
The ongoing therapeutical approaches to target NK cells in oncological patients and their advantages and 
disadvantages are listed.  
 
NK cells for adoptive therapy were later derived from different sources. They can be 
obtained in either autologous (from the patient) or allogeneic (from a healthy donor) settings 
[267]. Clinical trials in AML have reported that the treatment with haploidentical NK cells 
caused complete remissions in patients with poor prognosis and 100% disease-free survival in 
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a pediatric cohort [266, 268, 269]. Conversely, KIR mismatch treatment is not protective in 
any other haematological cancer than AML and several studies showed that the transfer of 
autologous NK cells does not influence the clinical response in patients with renal-cell 
carcinoma, advanced gastrointestinal cancer and metastatic melanoma [266, 270, 271].  
The combination of different cytokines (i.e. IL-2, IL-12, IL-15, IL-18, IL-21) has been tested 
to activate NK cells before transfer. It was reported that IL-15-stimulated NK cell treatment 
led to a clinical response in pediatric patients with solid tumors [272, 273]. Ongoing clinical 
trials have been testing the potential of NK cell transfer in combination with IL-15 in both 
solid cancer and hematological cancer patients (NCT01385423 and NCT01875601) and anti-
CD19 CAR-engineered NK cells in B-ALL patients (NCT00995137 and NCT01974479). In 
the last few years, the manipulation of NK cells ex-vivo has significantly improved and since 
the number of circulating NK cells is very low and naïve NK cell cytotoxicity can be 
enhanced, various protocols have been developed to expand NK cells with a higher antitumor 
potential. Nevertheless, the promising potential of adoptive transfer therapies with NK cells is 
still hampered by the high sensitivity to manipulation and cryopreservation and the low 
transfection efficiency of these cells.  
 
Enhancing NK cell activation and releasing NK cell inhibition 
NK cell functionality can be improved by targeting immunosuppressive factors or blocking 
inhibitory receptors and, on the other hand, by administrating activating ligands or cytokines, 
or targeting activating receptors. For example, treatment with recombinant IL-15 or IL-15-
IL15Rα complexes is being tested in metastatic patients in clinical trials (NCT02099539, 
NCT01385423 and NCT01875601) [274]. Among the inhibitory cytokines, TGF-β is the 
major suppressor of NK cell functions and a pharmaceutical inhibitor of TGF-β signaling 
(galunisertib) is being tested in a clinical trial in cancer patients (NCT02304419). 
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Moreover, NK cells, together with myeloid cells, are involved in ADCC and may contribute 
to the efficacy of several tumor-targeting monoclonal antibodies (e.g. trastuzumab, cetuximab 
and rituximab, targeting HER2, EGFR and CD20, respectively) [275, 276]. In this regard, 
bispecific or trispecific killer-cell engagers (BiKE or TriKE), which bind CD16 and tumor 
antigens, have been developed to favour the engagement of CD16 and the ADCC response 
[277, 278]. BiKEs that bind tumor antigens and NKG2D have been also designed and tested 
in preclinical studies in models of multiple myeloma [279].  
A recent “breakthrough” in oncological treatments is the discovery of checkpoint molecules 
and the development of checkpoint inhibitors [280-288]. In some conditions, activated NK 
cells can express PD-1 and CTLA4, which are targets of several FDA-approved cancer 
immunotherapy drugs, originally designed to reverse T cell exhaustion. In multiple myeloma 
patients, it was observed that NK cells expressed PD-1 and anti-PD-1 treatment reestablished 
NK cell antitumor activity [289-291]. In addition, Tim-3 expression was demonstrated to 
correlate with a poor prognosis and Tim-3 blockade restored NK cell activities in melanoma 
patients [292]. NK cells were also shown to exert ADCC against cancer cells after treatment 
with an anti-PDL1 monoclonal antibody [293]. The contribution of CTLA4 blockade in 
boosting NK cell activity is still unclear and might be indirect and dependent on T cell re-
activation [294, 295]. Finally, the neutralization of the classical inhibitory receptors of NK 
cells has been also tested. Indeed, the blocking mAb IPH2101, which recognizes KIR2DL-1, 
KIR2DL-2 and KIR2DL-3 and therefore blocks KIR-mediated inhibition triggered by HLA-C 
(both group 1 and 2), had no effect as a single agent in patients with multiple myeloma but it 
is being currently tested in combination in eight clinical trials in patients with solid and 
hematological cancer [296-298]. A monoclonal antibody blocking NKG2A (monalizumab) 
has been recently designed and there are several ongoing clinical trials for the treatment of 
CLL and various carcinomas [299].  
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Given the success of checkpoint inhibitors in oncological treatments, the characterization of 
novel targets or combinations to unleash the antitumor potential of cytotoxic lymphocytes is 
now crucial.  
2.2.7 NK cells and viruses 
 
NK cells play a crucial role in controlling viral infections and indeed, patients with an 
impaired NK cell number or functionality show recurrent varicella virus, papillomavirus and 
herpes virus infections [300-305]. The model of murine cytomegalovirus (MCMV) has been 
widely characterized and used to highlight not only the importance of NK cells in viral 
clearance, but also to appreciate the molecular mechanisms of NK cell-mediated control of 
viral spread, NK cell crosstalk with other immune cell types, the viral evasion process and the 
coevolution of viral species and the immune response. Finally, the MCMV model has 
highlighted the novel concepts of specificity of NK cells towards certain viral antigens and 
the consequent expansion of a specific long-lived “memory” NK cell population [300, 306, 
307]. The NK cell response to CMV infection, which is a controlled but persistent infection in 
immunocompetent individuals, occurs early upon infection and drives the expansion, 
contraction and persistence of a CMV-specific NK cell population, defined as Ly49H+ in the 
mouse and NKG2C+ in humans [306, 308-310]. In the murine model, it was clearly 
demonstrated that NK cell-mediated clearance of viral infected cells is dependent on a 
specific viral-encoded protein (m157), recognized by the activating receptor Ly49H, which 
induces IFNγ production and cytotoxicity [300, 311, 312]. Ly49H+ cells that persist after the 
first encounter with the virus are considered “memory” NK cells, which confer specific 
protection upon re-challenge with CMV, but not with other heterologous infections [309]. In 
addition, mouse models of herpes simplex virus, simian immunodeficiency virus (SIV) and 
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influenza infections also unveiled the NK cell-dependent contribution of viral control and the 
existence of a NK memory population [313-317]. Moreover, the expansion and persistence of 
CD57+NKG2C+ “memory” NK cells, which specifically recognize HLA-E on infected cells, 
was reported in CMV positive individuals [310, 318, 319]. Activating cytokines produced by 
myeloid cells (i.e. IL-12, IL-18, IL-15) are also crucial to induce NK cell activation. On the 
other hand, NK cells were shown to favor neutrophil activation via IFNγ and GM-CSF and 
macrophage, dendritic cell and T cell migration, activation and polarization [320-322]. 
Finally, NK cells were shown to be able to kill viral-infected immune cells to prevent viral 
spread. For example, in HIV-1 pregnant patients, decidual NK cells were reported to kill 
infected macrophages, but the mechanism is not fully elucidated [323]. Further studies are 
needed to elucidate the interplay of NK cells with other cell types in the delicate balance of 
viral control and the regulation of immunopathology.  
2.2.8 NK cell involvement in autoimmune reactions 
 
Autoimmune diseases exhibit great diversity in clinical symptoms and causative molecular 
mechanisms but they all share the presence of an autoreactive adaptive response, dependent 
on B and/or T cell activation against self-antigens [324]. The involvement of NK cells in 
autoimmune pathologies has been poorly characterized and it is quite controversial. Indeed, 
mouse models and correlative studies in patients have suggested either a protective or a 
promoting role of NK cells in autoimmune reactions [324]. In rheumatoid arthritis (RA), 
synovium-infiltrating NK cells have been detected in patients and they were shown to be 
mainly CD56bright and express higher levels of IFNγ compared to the circulating counterpart 
and to favor the activation and differentiation of monocytes, thus promoting the disease 
progression [325-327]. Moreover, genetic association studies have unveiled correlations of 
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allelic variations of KIRs, which favor NK cell activation, with the development of systemic 
lupus erythematosus (SLE), systemic sclerosis, psoriatic arthritis and type 1 diabetes mellitus 
[328-332]. In addition, an overexpression of NKG2D ligands (MIC molecules) was observed 
in a model of gluten-sensitive enteropathy and in patients with Crohn’s disease and RA, 
suggesting a possible disruption of NK cell tolerance and an uncontrolled NK cell 
cytotoxicity [324, 333, 334]. To date, antirheumatic drugs have not specifically targeted NK 
cells, but they may be involved in the efficacy of therapies with monoclonal antibodies 
because of the ADCC activity. Indeed, In multiple sclerosis patients, treatment with anti-IL-
2Rα (daclizumab) was associated with an increased number of circulating CD56bright NK 
cells, this correlated with positive clinical outcomes and ex-vivo cultures showed that NK 
cells were able to kill autoreactive T cells [335, 336]. Conversely, NK cell deficiency 
correlated with some clinical manifestations, such as thrombocytopenia and nephritis in SLE 
patients [325]. NK cells can produce IL-10 in certain conditions and therefore modulate the 
pathological immune response in rheumatic diseases, even though little is known about IL-10-
producing NK cells [337, 338]. Thus, NK cell role in autoimmunity is still controversial and 
further careful analysis of the role of NK cells in each disease stage, in different tissues and 
combining genetic and functional studies might help in the development of novel therapeutic 
strategies.   
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3. Rational and aim of the work 
 
The general purpose of this investigation was to characterize the role of IL-1R8/TIR8, an IL-1 
family receptor, in NK cells. IL-1 family members are key mediators of immunity and 
inflammation and play a major role in the regulation of innate and adaptive lymphocyte 
differentiation, polarization and activation. IL-1R8 acts as a negative regulator of ILRs and 
TLRs and it is therefore a crucial tuner of inflammatory responses. Previous evidences 
suggested that human NK cells expressed high levels of IL-1R8 and the role of this receptor 
in NK cells had not been described yet. NK cell activation is tightly regulated by a delicate 
balance between activating and inhibitory signals, which is crucial to avoid NK cell self-
reactivity and NK cell detrimental responses. We hypothesized that IL-1R8 could act as a 
negative regulator of NK cells and we aimed at characterizing its role in the modulation of 
NK cell development and effector functions.  
Among the inflammatory mediators regulated by IL-1R8, IL-18 was first described as 
“interferon-γ (IFN-γ)-inducing factor” and it is an essential molecule involved in Th1 and NK 
cell responses. Moreover, ILR and TLR pathways can be also targeted by IL-1R8 and were 
shown to contribute to NK cell activation, even though their direct functionality in NK cells is 
still matter of debate. For instance, IL-1β was shown to be involved in human NK cell 
development and activation and microbiota-derived TLR agonists were shown to contribute to 
NK cell differentiation. Thus, we first dissected the role of IL-1R8 in NK cell regulation and 
the mechanism responsible for this regulation. Since NK cells are fundamental players in 
tumor surveillance and viral control, we then assessed the relevance of IL-1R8-mediated 
regulation in pathological contexts. Given the promising strategies in oncological treatments 
acting on inhibitory pathways of the immune system, the characterization of novel inhibitory 
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pathways in cytotoxic lymphocytes such as NK cells, may have important clinical 
applications.  
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4. Methods 
 
 
4.1 Animals 
 
All female and male mice used were on a C57BL/6J genetic background and 8-12 weeks-old, 
unless specified. Wild-type mice were obtained from Charles River Laboratories, Calco, Italy 
or were littermates of Il1r8-/- mice. IL-1R8-deficient mice were generated as described [30]. 
Il1r1-/- mice were purchased from The Jackson Labs, Bar Harbor ME, USA. All colonies were 
housed and bred in the SPF animal facility of Humanitas Clinical and Research Center in 
individually ventilated cages. Il1r1-/-/Il1r8-/- mice were generated by crossing Il1r1-/- and 
Il1r8-/- mice. Il18-/-/Il1r8-/- were generated by crossing Il18-/- and Il1r8-/- mice. Mice were 
randomized based on sex, age and weight.  
Procedures involving animals handling and care were conformed to protocols approved by the 
Humanitas Clinical and Research Center (Rozzano, Milan, Italy) in compliance with national 
(D.L. N.116, G.U., suppl. 40, 18-2-1992 and N. 26, G.U. March 4, 2014) and international 
law and policies (EEC Council Directive 2010/63/EU, OJ L 276/33, 22-09-2010; National 
Institutes of Health Guide for the Care and Use of Laboratory Animals, US National Research 
Council, 2011). The study was approved by the Italian Ministry of Health (approvals n. 
43/2012-B, issued on the 08/02/2012 and n. 828/2015-PR, issued on the 07/08/2015). All 
efforts were made to minimize the number of animals used and their suffering. In most in vivo 
experiments, the investigators were unaware of the genotype of the experimental groups. 
Sample size was defined in order to detect differences of 20% or grater between the groups 
(10% significance level and 80% power). 
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4.2 Human primary cells 
 
Human peripheral mononuclear cells (PBMCs) were isolated from peripheral blood of healthy 
donors, upon approval by Humanitas Research Hospital Ethical Committee. PBMCs were 
obtained through a Ficoll density gradient centrifugation (GE Healthcare Biosciences). NK 
cells were then purified by a negative selection, using a magnetic cell-sorting technique 
according to the protocols given by the manufacturer (EasySep™ Human NK Cell 
Enrichment Kit, Stem Cell Technology). Human monocytes were obtained from peripheral 
blood of healthy donors by two-step gradient centrifugation, first by Ficoll and then by 
Percoll (65% iso-osmotic; Pharmacia, Uppsala, Sweden). Residual T and B cells were 
removed from monocyte fraction by plastic adherence. Monocytes were cultured in RPMI-
1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 1% L-Glutamine, 1% 
Pen/Strept and 100 ng/ml M-CSF (Peprotech) for 7 days in order to generate resting 
macrophages. T and B cells were obtained from peripheral blood of healthy donors using 
RosetteSep™ Human T Cell Enrichment Cocktail and RosetteSep™ Human B Cell 
Enrichment Cocktail (Stem Cell Technology), following the manufacturer's instructions. 
Neutrophils were enriched from Ficoll–isolated granulocytes, using EasySep™ Human 
Neutrophil Enrichment Kit (StemCell Technologies), according to the manufacturer’s 
instructions. 
To analyse pluripotent haematopoietic stem cells (HSC) and NK cell precursors (NKP), 
human Bone Marrow mononuclear cells were collected from Humanitas Biobank, upon 
approval by Humanitas Research Hospital Ethical Committee (Authorization 1516, issued on 
February 26, 2016). Frozen samples were thawed and vitality was assessed by trypan blue and 
Aqua LIVE/Dead-405 nm staining (Invitrogen), before flow cytometry analysis. 
Informed consent was obtained from all subjects. 
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4.3 FACS analysis 
 
Single-cell suspensions of BM, blood, spleen, lung and liver were obtained and stained. 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience) was used for intracellular 
staining of Granzyme B and Perforin. Cytofix/Cytoperm (BD Biosciences) was used for 
intracellular staining of IFNγ. Liver ILC1 were identified as NK1.1+CD3-CD49a+CD49b- 
cells. Formalin 4% and Methanol 100% were used for intracellular staining of IRAK4, 
pIRAK4, pS6 and JNK. The following murine antibodies were used: CD45-BV605, -BV650 
or -PerCp-Cy5.5 (Clone 30-F11); CD45.1-BV650 (Clone A20); CD45.2-APC, -BV421 
(Clone 104); CD3e-PerCP-Cy5.5 or -APC (Clone 145-2C11); CD19-PerCP-Cy5.5, -
eFluor450 (Clone 1D3); NK1.1-PE, -APC, -eFluor450 or –Biotin (Clone PK136); CD11b-
BV421, -BV450, -BV785 (Clone M1/70); CD27-FITC or –APC-eFluor780 (Clone LG.7F9); 
CD4-FITC (Clone RM 4-5); CD8-PE (Clone 53-6.7); KLRG-1-BV421 (Clone 2F1); 
NKG2D-APC (Clone CX5); DNAM-1-APC (Clone 10E5); Ly49H-PECF594 (Clone 3D10); 
Granzyme B-PE (Clone NGZB); Perforin-PE (Clone eBioOMAK-D); IFNγ-Alexa700 or -
APC (Clone XMG1.2); CD107a-Alexa647 (Clone 1D4B); FasL-APC (Clone MFL3);  
Lineage Cell Detection Cocktail-Biotin; Sca-1-FITC (Clone D7); CD117-PE or -Biotin 
(Clone 3C11); CD127-eFluor450 (Clone A7R34); CD135-APC or –Biotin (Clone A2F10.1); 
CD244-PE (Clone 2B4); CD122-PE-CF594 (Clone TM-Beta1); CD49b-PE-Cy7 or Biotin 
(Clone DX5), CD49a-APC (Clone Ha31/8), from BD Bioscience, eBioscience, BioLegend or 
Miltenyi Biotec. The following human antibodies were used: CD56-PE (Clone CMSSB); 
CD3-FITC (Clone UCHT1); CD16-Pacific Blue (Clone 3G8); CD34-PE-Vio770 (Clone 
AC136); CD117-BV605 (Clone 104D2); NKp46-BV786 (Clone 9E2/NKp46); CD45-PerCP 
(Clone 2D1); CD19-APC-H7 (Clone SJ25C1); CD14-APC-H7 (Clone M5E2); CD66b-APC-
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Vio770 (Clone REA306), from BD Bioscience, eBioscience or Miltenyi Biotec. Biotinylated 
anti-hSIGIRR (R&D Systems) and Streptavidin-Alexa647 (Invitrogen™) were used to stain 
IL-1R8 in human cells. Human NKT cells were detected using PE-CD1d tetramers loaded 
with αGalCer (ProImmune, Oxford, UK). Antibodies to detect protein phosphorylation were 
as follows: p-IRAK4 Thr345/Ser346 (Clone D6D7), IRAK4, p-S6-Alexa647 Ser235/236 
(Clone D57.2.2E); p-SAPK/JNK Thr183/Tyr185 (Clone 81E11), from Cell Signaling 
Technology. A Goat anti-Rabbit-Alexa647 secondary antibody (Invitrogen™) was used to 
stain p-IRAK4, IRAK4 and p-SAPK/JNK. Results are reported as mean fluorescence 
intensity (MFI) normalized on isotype control or fluorescence minus one (FMO). Cell 
viability was determined by Aqua LIVE/Dead-405 nm staining (Invitrogen) or Fixable 
Viability Dye (FVD) eFluor® 780 (eBioscience), negative cells were considered viable. Cells 
were analyzed on LSR Fortessa or FACSVerse (BD Bioscience). Data were analyzed with 
FlowJo software (Treestar).  
 
4.4 Quantitative PCR 
 
Total RNA was extracted using Trizol reagent (Invitrogen) following the manufacturer’s 
recommendations. RNA was further purified using miRNeasy RNA isolation kit (QIAGEN) 
or Direct-zol™ RNA MiniPrep Plus (Zymo Research). cDNA was synthesized by reverse 
transcription using High Capacity cDNA archive kit (Applied Biosystems) and quantitative 
real-time PCR was performed using the SybrGreen PCR Master Mix (Applied Biosystems) in 
a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad). PCR reactions were carried 
out with 10 ng of DNA. Data were analyzed with the Δ2CT method. Data were normalized 
based on GAPDH, βactin or 18S expression, as indicated, determined in the same sample. 
Analysis of all samples was performed in duplicate. Primers were designed according to the 
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published sequences and listed as follows: s18/S18: forward 5'-ACT TTC GAT GGT AGT 
CGC CGT-3', reverse 5'- CCT TGG ATG TGG TAG CCG TTT-3'; Gapdh/GAPDH: forward 
5'-GCA AAG TGG AGA TTG TTG CCA T-3', reverse 5'-CCT TGA CTG TGC CGT TGA 
ATT T-3'; βactin/βACTIN: forward 5'- CCC AAG GCC AAC CGC GAG AAG AT-3', 
reverse 5'- GTC CCG GCC AGC CAG GTC CAG -3'; il1r8: forward 5'- AGA GGT CCC 
AGA AGA GCC AT-3', reverse 5'- AAG CAA CTT CTC TGC CAA GG-3'; IL1R8: forward 
5'- ATG TCA AGT GCC GTC TCA ACG -3', reverse 5'- GCT GCG GCT TTA GGA TGA 
AGT-3'; il1r1: forward 5’- TGC TGT CGC TGG AGA TTG AC -3’, reverse 5’- TGG AGT 
AAG AGG ACA CTT GCG AA -3’; il1r2: forward 5’- AGT GTG CCC TGA CCT GAA 
AGA -3’, reverse 5’- TCC AAG AGT ATG GCG CCC T -3’; il1r3: forward 5’- GGC TGG 
CCC GAT AAG GAT -3’, reverse 5’- GTC CCC AGT CAT CAC AGC G -3’; il1r4: forward 
5’- GAA TGG GAC TTT GGG CTT TG -3’, reverse 5’- GAC CCC AGG ACG ATT TAC 
TGC -3’; il1r5: forward 5’- GCT CGC CCA GAG TCA CTT TT -3’, reverse 5’- GCG ACG 
ATC ATT TCC GAC TT -3’; il1r6: forward 5’- GCT TTT CGT GGC AGC AGA TAC -3’, 
reverse 5’- CAG ATT TAC TGC CCC GTT TGT T -3’; 16S: forward 5’- AGA GTT TGA 
TCC TGG CTC AG -3’, reverse 5’- GGC TGC TGG CAC GTA GTT AG -3’.  
 
4.5 Purification of murine leukocytes 
 
Splenic NK cells and bone marrow neutrophils were MACS enriched according to 
manufacturer’s instructions (Miltenyi Biotec). Purity of NK cells was about 90% as 
determined by FACS. Purity of neutrophils was ≥ 97.5%. NK cells were stained (CD45-
BV650, NK1.1-PE, CD3e-APC, CD11b-BV421, CD27-FITC) and sorted on a FACSAria cell 
sorter (BD Bioscience) to obtain high purity NK cells and NK cell populations 
(CD11blowCD27low, CD11blowCD27high, CD11bhighCD27high and CD11bhighCD27low). Splenic 
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B and T lymphocytes were stained (CD45-PerCP, CD3e-APC, CD4-FITC, CD8-PE, CD19-
eFluor450) and sorted. Purity of each population was ≥ 98%. Resulting cells were processed 
for mRNA extraction or used for adoptive transfer or co-culture experiments. In vitro-derived 
macrophages were obtained from bone marrow total cells. Bone marrow cells were cultured 
in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 1% L-Glutamine, 
1% Pen/Strept and 100 ng/ml M-CSF (Peprotech) for 7 days in order to generate resting 
macrophages. Bone marrow cells were cultured in RPMI-1640 medium supplemented with 
10% Fetal Bovine Serum (FBS), 1% L-Glutamine, 1% Pen/Strept and 20 ng/ml GM-CSF 
(Peprotech) for 7 days in order to generate DCs. 
 
4.6 Confocal microscopy 
 
Murine splenic NK cells were MACS enriched, let adhere on poly-D-Lysine (Sigma-Aldrich) 
coated coverslips, fixed with 4% PFA, permeabilized with 0.1% Triton X-100, incubated with 
blocking buffer (5% normal donkey serum (Sigma-Aldrich), 2% BSA, 0.05% Tween). Cells 
were then stained with biotin-conjugated goat polyclonal anti-SIGIRR antibody or biotin-
conjugated normal goat IgG as control (both R&D Systems) (10µg/ml) followed by Alexa 
Fluor 488–conjugated donkey anti-goat IgG antibody (Molecular Probes) and DAPI 
(Invitrogen). Coverslips were mounted with the antifade medium FluorPreserve Reagent 
(EMD Millipore) and analyzed with an Olympus Fluoview FV1000 laser scanning confocal 
microscope with oil immersion lens 40× (N.A.1.3). 
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4.7 Stimulated emission depletion (STED) microscopy  
 
Human NK cells were enriched and let adhere on poly-D-Lysine (Sigma-Aldrich) coated 
coverslips, stimulated with IL-18 (50 ng/ml; 1 min, 5 min, 10 min), fixed with 4% PFA, 
incubated with 5% normal donkey serum (Sigma-Aldrich), 2% BSA, 0.05% Tween in PBS2+ 
(pH 7.4) (blocking buffer), and then with biotin-conjugated goat polyclonal anti-human IL-
1R8 antibody or biotin-conjugated normal goat IgG (all from R&D Systems) and mouse 
monoclonal anti-IL-18Rα (Clone 70625; R&D System) or mouse IgG1 (Invitrogen), all 
diluted at 5µg/ml in blocking buffer, followed by Alexa Fluor 488– conjugated donkey anti-
goat IgG antibody and Alexa Fluor 555 donkey anti-mouse IgG antibody (both from 
Molecular Probes). Mowiol was used as mounting medium. STED xyz images were acquired 
in a unidirectional mode with a Leica SP8 STED3X confocal microscope system. Alexa Fluor 
488 was excited with a 488nm Argon Laser and emission collected from 505 to 550 nm 
applying a gating between 0.4 to 7ns to avoid collection of reflection and autofluorescence. 
Alexa Fluor 555 was excited with a 555/547nm-tuned white light laser (WLL) and emission 
collected from 580 to 620 nm. Line sequential acquisition was applied to avoid fluorescence 
overlap. The 660nm CW-depletion laser (80% of power) was used for both excitations. 
Images were acquired with Leica HC PL APO 100x/1.40 oil STED White objective at 
572.3mAU. CW-STED and gated CW-STED were applied to Alexa-488nm and Alexa Fluor 
555, respectively. Collected images were de-convolved with Huygens Professional software. 
 
4.8 3′-mRNA Sequencing and Analysis 
 
Splenic NK cells  (from 6 mice per genotype and pooled in pairs) were purified as described 
above and stimulated with IL-18 (MBL) (20 ng/ml for 4 h). RNA was prepared as described 
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above. The QuantSeq 3′mRNA-seq Library Prep Kit for Illumina (Lexogen) was used to 
generate libraries, which were sequenced on the NextSeq (Illumina; 75 bp PE).  The fastq 
sequence files were assessed using the fastqc program. The reads were first trimmed using 
bbduk in the bbmap suite of software to remove the first 12 bases and a contaminant kmer 
discovery length of 13 was used for contaminant removal. Regions of length 20 or above with 
average quality of less than 10 were trimmed from the end of the read. The reads were then 
trimmed to remove trailing polyG and polyA runs using cutadapt and the quality of the 
remaining reads reassessed with fastqc. The trimmed reads were aligned to the mm10 
genomic reference and reads assigned to features in the mm10 annotation using the STAR 
program [339]. Differential expression analysis was performed using the generalized linear 
model (GLM) functions in the R/bioconductor [340] edgeR package [341] with TMM 
normalization. Gene set analysis was performed using the romer function in the 
R/bioconductor package limma [342, 343]. Metascape (http://metascape.org) was used to 
enrich genes for GO biological processes, KEGG Pathway and Reactome Gene Sets.  
 
4.9 Measurement of cytokines  
 
BD Cytometric Bead Array (CBA) mouse inflammation kit (BD) or Duoset ELISA kits 
(R&D System) were used to measure cytokines.  
 
4.10 In vitro functional assays 
 
Total murine splenocytes or enriched murine or human NK cells were cultured in RPMI-1640 
medium supplemented with 10% Fetal Bovine Serum (FBS) 1% L-Glutamine, 1% Pen/Strept 
and treated with IL-2, IL-12, IL-15 (Peprotech), IL-18 (MBL), IL-1β (Peprotech) and PMA-
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Ionomycin (Sigma-Aldrich), as specified. FasL expression was evaluated upon treatment for 
45 minutes with IL-18 (50 ng/ml), IL-15 (50 ng/ml), IL-2 (20 ng/ml) and IL-12 (10 ng/ml). 
IFNγ production was analysed upon 16 hours of treatment with IL-12 (20 ng/ml) and IL-18 
(20 ng/ml) or IL-1β (20 ng/ml), by intracellular staining using BD Cytofix/CytopermTM 
Fixation/Permeabilization Kit, following the manufacturer's instructions, or by ELISA. 
Granzyme B and Perforin intracellular staining was performed upon 18 hours of stimulation 
with IL-12 (10 ng/ml), IL-15 (10 ng/ml) and IL-18 (50 ng/ml), using Foxp3/Transcription 
Factor Staining Buffer Set (eBioscience). CD107a-Alexa647 antibody was added during the 
4-hour culture and analysed by flow cytometry.  BD GolgiPlugTM (containing Brefeldin) and 
BD GolgiStopTM (containing Monensin) were added 4 hours prior to intracellular staining. 
PMA (50 ng/ml)- Ionomycin (1 µg/ml) were added 4 hours prior to intracellular staining, 
when specified. 
NK-DC co-culture experiments were performed as previously described [193]. DCs were 
treated with LPS from Escherichia coli O55:B5 (Sigma-Aldrich; 1µg/ml) or CpG ODN 1826 
(Invivogen; 3µg/ml) and with anti-mIL-18 neutralizing antibody (BioXCell, Clone YIGIF74-
1G7; 5µg/ml) or Rat Isotype Control (BioXCell, Clone 2A3). 
IFNγ and CD107a expression upon viral infection was analyzed by flow cytometry upon 4-
hour treatment with BD GolgiPlugTM, BD GolgiStopTM and IL-2 (500U/ml).  
Phosphorylation of IRAK4, S6 and JNK was analyzed upon 15-30 minutes of stimulation 
with IL-18 (10 ng/ml). 
 
4.11 Human primary NK cell transfection 
 
Human NK cells were enriched from peripheral blood of healthy donors and transfected with 
Dharmacon™ Acell™ siRNA (GE Healthcare) using Accell™ delivery medium (GE 
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Healthcare), following the manufacturer’s instructions. 1 µM SIGIRR-specific siRNA (On-
Target Plus; Dharmacon, GE Healthcare) comprised 250 nM of the four following antisense 
sequences: I, AGU UUC GCG AGC CGA GAU CUU; II, UAC CAG AGC AGC ACG UUG 
AUU; III, UGA CCC AGG AGU ACU CGU GUU; IV, CUU CCC GUC GUU UAU CUC 
CUU (all 5’ to 3’). 
  
4.12 Generation of bone marrow chimeras 
 
Il1r8-/- and Il1r8+/+ mice were lethally irradiated with a total dose of 900 cGy. 2 h later, mice 
were injected in the retro-orbital plexus with 4x106 nucleated bone marrow cells obtained by 
flushing of the cavity of freshly dissected femurs from wild type or Il1r8-/- donors. 
Competitive bone marrow chimeric mice were generated by reconstituting recipient mice with 
50% CD45.1 Il1r8+/+ and 50% CD45.2 Il1r8-/- bone marrow cells. Recipient mice received 
gentamycin (0.8 mg/ml in drinking water) starting 10 days before irradiation and for 2 weeks 
after irradiation. NK cells of chimeric mice were analyzed 8 weeks after bone marrow 
transplantation.  
 
4.13 Depletion and blocking experiments 
 
Mice were treated intraperitoneally with 200 µg of specific mAbs (Mouse anti-NK1.1, Clone 
PK136; Mouse Isotype Control, Clone C1.18.4; Rat anti-mIL-18, Clone YIGIF74-1G7; Rat 
Isotype Control, Clone 2A3; Rat anti-IFNγ, Clone XMG1.2; Rat IgG1 HRPN; Mouse anti-IL-
17A, Clone 17F3; Mouse Isotype Control, Clone MOPC-21; Rat anti-CD4/CD8, Clone 
GK1.5/YTS; Rat Isotype Control, Clone LTF-2 (all from BioXCell)) and then with 100 µg 
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once (anti-NK1.1) or three times (anti-IL-18, anti-IFNγ, anti-IL-17A, anti-CD4/CD8) a week 
for the entire duration of the experiment.  
Anti-NK1.1 treatment was used for the entire duration of the experiment in DEN-induced 
hepatocellular carcinoma model, which lasts 12-14 months. NK cell depletion was checked in 
the first months, after 6 months and at sacrifice. NK1.1+ cells were depleted, but it should be 
considered that other NK1.1-expressing cell types (NKT cells and ILC1) are affected by the 
depletion. 
 
4.14 Microflora depletion 
 
6-week-old mice were treated every day for 5 weeks by oral gavage with a cocktail of 
antibiotics [ampicillin (Pfizer) 10 mg/ml, vancomycin (PharmaTech Italia) 10 mg/ml, 
metronidazol (Società Prodotti Antibiotici) 5 mg/ml and neomycin (Sigma-Aldrich) 10 
mg/ml]. Control mice were treated with drinking water. A gavage volume of 10 ml/kg body 
weight was delivered with a stainless steel tube without prior sedation of mice. DNA was 
isolated from bacterial fecal pellets with PowerSoil® DNA Isolation Kit (MO BIO 
Laboratories, Inc.) and quantified by spectrophotometry at 260 nm. PCR was performed with 
10 ng of DNA using the SybrGreen PCR Master Mix (Applied Biosystems) in a CFX96 
Touch™ Real-Time PCR Detection System (Bio-Rad). Data were analyzed with the Δ2CT 
method (Applied Biosystems, Real-Time PCR Applications Guide).  
 
4.15 Cancer models 
 
Mice were injected intraperitoneally (i.p.) with 25 mg/kg of diethylnitrosamine (DEN, Sigma) 
at 15 days of age. Mice were sacrificed 6-8-10-12 months later, to analyze liver cancer. Liver 
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cancer score was based on number and volume of lesions (0: no lesions; 1: lesion number<3, 
or lesion dimension <3mm; 2: lesion number<5, or lesion dimension <5mm; 3: lesion 
number<10, or lesion dimension <10mm; 4: lesion number<15, or lesion dimension <10mm; 
5: lesion number>15, or lesion dimension >10mm). Lung metastasis experiments were 
performed injecting i.m. the 3-MCA derived mycoplasma-free sarcoma cell line MN/MCA1 
(105 cells/mouse in 100 µl PBS) [344]. Primary tumor growth was monitored twice weekly, 
and lung metastases were assessed by in vivo imaging and by macroscopic counting at 
sacrifice 25 days after injection. Liver metastases were generated by injecting intrasplenically 
1.5x105 mycoplasma-free colon carcinoma cells (MC38) [345]. Mice were sacrificed 12 days 
after injection and liver metastasis were counted macroscopically. MC38 cells were received 
from ATCC just before use. MN/MCA1 cells were authenticated morphologically by 
microscopy in vitro and by histology ex vivo. Tumor size limit at which mice were sacrificed 
was based on major diameter (≤ 2cm). 
 
4.16 Viral infections 
 
Mice were injected intravenously (i.v.) with 5×105 PFU of the tissue culture (TC)-grown virus 
in PBS. Wild-type MCMV or mutant MCMV lacking m157  were used as indicated [346]. 
Bacterial artificial chromosome (BAC)-derived MCMV strain MW97.01 has been previously 
shown to be biologically equivalent to MCMV strain Smith (VR-1399) and is hereafter 
referred to as wild-type (WT) MCMV [347]; mutant m157 MCMV is named Δm157 MCMV. 
Mice were sacrificed 1.5 and 4.5 days post infection and viral titer was assessed by plaque 
assay, as previously described [348, 349]. Newborn mice were infected i.p. with 2000 PFU of 
the MCMV strain MW97.01 and sacrificed at day 7 post infection. Viral titer was assessed by 
plaque assay, as previously described [348, 349]. 
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4.17 Adoptive transfer 
 
106 Il1r8+/+ or Il1r8-/- sorted NK cells were injected i.v. in wild type adult mice 5 hours before 
MN/MCA or MC38 injection, or i.p. in newborn mice 48 hours after MCMV injection. 
Adoptively transferred NK cell engraftment, proliferative capacity and functionality (IFNγ 
production and degranulation after ex vivo stimulation) were assessed 3 and 7 days after 
injection. 
 
4.18 In vivo proliferation  
 
In vivo proliferation was measured using Click-iT® Edu Flow Cytometry Assay Kit 
(Invitrogen). Edu was injected i.p. (0.5 mg/mouse), mice were sacrificed 24 hours later and 
cells were stained following the manufacturer’s instructions and analyzed by flow cytometry.  
 
4.19 Immunohistochemistry 
 
Liver frozen tissues were cut at 8 mm and then fixed with 4% PFA. Endogenous peroxidases 
were blocked with 0.03% of H2O2 for 5 min and unspecific binding sites were blocked with 
PBS + 1% FBS for 1h. Tissues were stained with polyclonal goat anti mouse NKp46/NCR1 
(R&D System) and goat on mouse HRP polymer kit (GHP516, Biocare Medical) was used as 
secondary antibody. Reactions were developed with 3,3’-Diaminobenzidine (DAB) (Biocare 
Medical) and then slides were counterstained with hematoxylin. Slides were mounted with 
eukitt (Sigma-Aldrich). 20X images were analyzed with cell^F software (Olympus). 
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4.20 In vivo Imaging 
 
After feeding with AIN-76A alfalfa-free diet (Mucedola srl, Italy) for two weeks, to reduce 
fluorescence background, mice were intravenously (i.v.) injected with XenoLight RediJect 2-
DeoxyGlucosone (DG) (PerkinElmer) and 24 hours later 2-DG fluorescence was measured 
using Fluorescence Molecular Tomography system (FMT 2000, Perkin Elmer). Acquired 
images were subsequently analyzed with TrueQuant 3.1 analysis software (Perkin Elmer). 
 
4.21 Statistical analysis 
 
For animal studies, sample size was defined on the basis of past experience on cancer and 
infection models, in order to detect differences of 20% or grater between the groups (10% 
significance level and 80% power). Values were expressed as mean ± SEM or median of 
biological replicates, as specified. One-way ANOVA or Kruskal-Wallis test were used to 
compare multiple groups. Two-sided unpaired Student’s t test was used to compare 
unmatched groups with Gaussian distribution and Welch’s correction was applied in case of 
significantly different variance. Mann-Whitney test was used in case of non-Gaussian 
distribution. ROUT test was applied to exclude outliers. p≤0.05 was considered significant. *p 
< 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented. Statistics were calculated with 
GraphPad Prism version 6, GraphPad Software.  
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5. Results 
	  
 
5.1 Role of IL-1R8 in NK cell differentiation and function 
5.1.1 IL-1R8 is differentially expressed in human and murine NK cell 
subpopulations 
 
IL-1R8 mRNA was originally observed in human primary NK cells by Northern blot analysis 
[34]. As shown in Figure 1, we confirmed IL-1R8 mRNA and protein expression in human 
NK cells purified from peripheral blood. IL-1R8 mRNA levels were considerably higher in 
peripheral blood NK cells, compared to other circulating leukocytes (e.g. T cells, B cells, 
neutrophils and monocytes) and in vitro-derived macrophages (Figure 1A). In agreement, IL-
1R8 protein expression level was higher, compared with NKT, T and B cells (Figure 1B). 
Upon sorting of NK subsets based on CD56 and CD16 expression, we observed that IL1R8 
mRNA level increased during NK cell maturation, and it was higher in the CD56dimCD16+ 
more mature subset compared to the CD56brCD16- subset (Figure 1C). Flow cytometry 
analysis showed that IL-1R8 expression pattern in each NK cell subset was in line with 
mRNA transcript levels (Figure 1D). Flow cytometry analysis of human bone marrow cells 
showed that IL-1R8 expression was acquired in early hematopoietic precursors (e.g. HSC), 
NK cell-committed precursors (e.g. NKP) and immature NK cells and it was selectively 
upregulated in mature NK cells, but not in T and NKT cells (Figure 1E). 
We next explored IL-1R8 expression on murine NK cells. Murine NK cells expressed high 
levels of Il1r8 mRNA, compared with other cell types (CD4+ T, CD8+ T and B cells, 
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neutrophils and in vitro-derived macrophages) and with other IL-1 family receptors in NK 
cells (Il1r1, Il1r2, Il1r3, Il1r4, Il1r5 and Il1r6) (Figure 1F, 1G). Confocal microscopy 
analysis showed that murine splenic NK cells express high levels of IL-1R8 cell-membrane 
protein (Figure 1H). In line with the result obtained in human NK cells, Il1r8 mRNA level 
increased during the 4-stage developmental transition from CD11blowCD27low to CD27low 
(Figure 1I). 
These results indicate that both human and murine NK cells express IL-1R8, which is 
upregulated during NK cell maturation. 
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Figure 1. IL-1R8 expression in NK cells. (a, b and c) IL-1R8 mRNA (a, c) and protein (b) expression in human 
primary NK cells, compared with T and B cells, neutrophils, monocytes and in vitro-derived macrophages (a) or 
T, B and NKT cells (b) and in human primary NK cell maturation stages (CD56brCD16-, CD56brCD16+, 
CD56dimCD16+), and in the CD56dimCD16- subset (c). (d) IL-1R8 protein expression in human primary NK cells 
and NK cell subsets. (e) IL-1R8 protein expression in human bone marrow precursors and mature cells. (f) IL-
1R8 mRNA expression in murine primary NK cells, compared with T and B cells, neutrophils, and in vitro-
derived macrophages. (g) IL-1 receptor family members (Il1r1, Il1r2, Il1r3, Il1r4, Il1r5, Il1r6, Il1r8) mRNA 
expression in murine primary NK cells isolated from the spleen. (h) IL-1R8 protein expression in murine NK 
cells by confocal microscopy. Magnification bar: 10µm. (i) Il1r8 mRNA expression in murine NK cell subsets 
(DN, CD11blow, DP and CD27low) sorted from splenic NK cells. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± 
SEM is represented) 
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5.1.2 IL-1R8-deficient NK cells display a more mature phenotype  
 
In order to address the role of IL-1R8 in NK cells, we analyzed the phenotype of NK cells in 
Il1r8-deficient mice. Both NK cell frequency among lymphocytes and NK cell absolute 
number were significantly higher in peripheral blood of Il1r8-/- compared to Il1r8+/+ mice. A 
minor increase was observed in the liver, but not in the spleen of Il1r8-/- mice, whereas 
frequency and absolute number were lower in the BM of Il1r8-/- mice (Figure 2A, 2B).   
We next analysed the maturation of NK cells in Il1r8-/- mice. In mice, most NK cells develop 
in the bone marrow [108, 141], and their maturation can be dissected/identified based on the 
expression of CD27, a TNF receptor family member, together with the integrin CD11b. 
During maturation, NK cells progressively acquire the expression on the cell surface of 
CD11b, while CD27 is gradually lost, resulting in tree subsets: CD11blow CD27high NK cells, 
CD11b high CD27 high NK cells and CD11b high CD27low NK cells [131]. In Il1r8-/- mice, the 
frequency of the CD27low subset was significantly higher compared to Il1r8+/+ mice 
(p<0.001) in BM, spleen and blood, indicating a more mature phenotype of NK cells (Figure 
2C). The increased frequency of the CD27low subset was counterbalanced by a reduction of 
the CD11bhighCD27high and CD11blowCD27high subsets in Il1r8-/- mice. Il1r8-/- NK cells 
collected from BM, spleen and blood expressed higher levels of the maturation marker 
KLRG1 (Figure 2D). Increased expression of KLRG1 was not associated to a specific NK 
subset (CD11blowCD27high, CD11bhighCD27high and CD11bhighCD27low) (Figure 2E), 
suggesting that the higher frequency of KLRG1+ NK cells in the whole NK cell population is 
due to higher frequency of CD11bhighCD27low NK cells. Finally, we analysed Ly49 receptors, 
which are clonally acquired during NK cell differentiation and we did not observed any 
difference in Il1r8-/- NK cells, compared to Il1r8+/+ NK cells  (Figure 2F). This suggests that 
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the NK cell education process is not altered in IL-1R8-deficient mice and IL-1R8 does not 
affect the MHCI-mediated licensing of NK cells. 
Since NK cell maturation occurs in the first 2-3 weeks of age [131], we investigated whether 
the more mature phenotype of NK cells occurred early during development of Il1r8-/- mice. 
As shown in Figure 3A and 3B, the frequency of CD27low and DP subsets was higher in Il1r8-
/- mice already at 2 and 3 weeks of age, indicating an early acquisition of a more mature 
phenotype in NK cells in newborn mice. Moreover, at 3 weeks of age, the number of total NK 
cells was higher in spleen and blood in Il1r8-/- mice (Figure 3A, 3B). We next addressed 
whether IL-1R8-deficiency affected the development of NK precursors in BM. As shown in 
Figure 3C, the frequency of hematopoietic stem cells (HSC), common lymphoid precursors 
(CLP), pre-NK precursors (pre-NKP) and NK precursors (NKP) was similar in Il1r8-/- and 
Il1r8+/+ mice. Collectively, these results suggest that IL-1R8 is involved in the regulation of 
NK cell maturation but does not affect NK cell commitment, and in absence of IL-1R8 NK 
cells display a more mature phenotype, which is early acquired in newborn mice. 
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Figure 2. NK cell differentiation in IL-1R8-deficient mice. (a, b) NK cell frequency and absolute number 
among leukocytes in bone marrow, spleen, blood and liver of Il1r8+/+ and Il1r8-/- mice. (c) NK cell subsets (DN, 
CD11blow, DP and CD27low) in bone marrow, spleen and blood of Il1r8+/+ and Il1r8-/- mice. (d, e) KLRG1 
expression in NK cells in bone marrow, spleen and blood of Il1r8+/+ and Il1r8-/- mice, in total NK cells (d) and 
NK cell subsets (e). (f) Frequency of Ly49A, Ly49D and Ly49G single positive, double positive and triple 
positive NK cells in Il1r8+/+ and Il1r8-/- mice. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is 
represented)  
 
 
Figure 3. Early stages of NK cell maturation. (a, b) NK absolute number and NK cell subsets (DN, CD11blow, 
DP and CD27low) in bone marrow, spleen and blood of Il1r8+/+ and Il1r8-/- newborn mice at 2 (a) and 3 (b) 
weeks of age. (c) Frequency of bone marrow precursors (HSC, CLP, pre-NKP, NKP) in Il1r8+/+ and Il1r8-/- 
mice. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
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5.1.3 IL-1R8-deficient NK cells express higher levels of activating receptors and 
display enhanced effector functions 
 
We next investigated whether IL-1R8 impacted on NK cell activities. We first analysed the 
expression of NKG2D and DNAM-1, two activating receptors involved in the recognition of 
tumor cells and in NK cell cytotoxicity. NKG2D expression was significantly upregulated in 
peripheral blood Il1r8-/- NK cells, in particular in CD11blowCD27high and CD11bhighCD27high 
subsets (Figure 4A). DNAM-1 expression was significantly increased only in 
CD11bhighCD27high NK cells (Figure 4B). We then characterized the expression of Ly49H, an 
activating receptor that specifically recognizes the MCMV encoded-protein m157. Higher 
levels of Ly49H were observed in Il1r8-/- NK cells, in particular in the CD11bhighCD27low 
subset (Figure 4C).  
 
Figure 4. IL-1R8-deficient NK cell effector functions. (a-c) NKG2D (a), DNAM-1 (b) and LY49H (c) 
expression in peripheral NK cells and NK cell subsets of Il1r8+/+ and Il1r8-/- mice. (d-g) IFNγ (d), Granzyme B 
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(e), perforin (f) and FasL (g) expression in Il1r8+/+ and Il1r8-/- NK cells and NK cell subsets upon ex-vivo 
stimulation. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
 
To establish whether IL-1R8 regulates NK cell effector functions, we evaluated IFNγ 
production and degranulation in Il1r8+/+ and Il1r8-/- NK cells, upon ex-vivo stimulation with a 
combination of IL-12 and IL-18. As shown in Figure 4D, IL-12/IL-18 stimulation drove a 
more sustained IFN-γ response in IL-1R8-deficient NK cells. The frequency of IFN-γ+ NK 
cells was higher in Il1r8-/- total NK cells and in each NK cell subset (CD11bhighCD27low, 
CD11bhighCD27high and CD11blowCD27high). This indicates that IFN-γ production was 
enhanced by the absence of IL-1R8 in all NK cells, independently from their maturation state. 
We then analysed the expression of cytotoxic mediators in Il1r8+/+ and Il1r8-/- NK cells, upon 
treatment with IL-12, IL-15 and IL-18. As shown in Figure 4E and 4F, the percentage of 
granzyme B+ NK cells was higher in absence of IL-1R8, whereas no difference in terms of 
perforin production was observed. Since IL-18 is also involved in the expression of FasL and 
activation of FasL-mediated killing by NK cells (Smyth MJ 2004), we assessed whether IL-
1R8 might regulate FasL expression. Indeed, Il1r8-/- NK cells expressed higher levels of 
FasL, upon stimulation with a combination of IL-2, IL-12, IL-15 and IL-18, suggesting that 
IL-1R8 could also negatively regulate FasL-dependent effector mechanisms in NK cells 
(Figure 4G). Overall, these results showed that IL-1R8 negatively regulates NK cell effector 
functions, suggesting that in absence of IL-1R8 NK cell activation threshold is lowered.  
  
 
 
87 
5.1.4 IL-1R8 directly regulates NK cell differentiation through a cell-
autonomous mechanism  
 
In addition to leukocytes, IL-1R8 is expressed by different cell types, including epithelial 
cells. To characterize the mechanism responsible for the more sustained NK cell 
differentiation and activation observed in the absence of IL-1R8 and dissect the contribution 
of the hematopoietic and non-hematopoietic compartments, we first generated bone-marrow 
chimeric mice. Il1r8+/+ or Il1r8-/- bone marrow cells were transplanted into either Il1r8+/+or 
Il1r8-/- recipients, and the phenotype of NK cells in these mice were analysed 9 weeks upon 
transplantation. As shown in Figure 5A and 5B, both absolute numbers and maturation stages 
of NK cells where not affected by the host genotype. Indeed, Il1r8+/+ NK cells developed in 
Il1r8-/- hosts had a phenotype overlapping that of Il1r8+/+ NK cells developed in Il1r8+/+ host 
and in turn, Il1r8-/- NK cells developed in Il1r8+/+ hosts resembled Il1r8-/- NK cells developed 
in Il1r8-/- hosts. Thus, IL-1R8-deficient BM drove the generation of a higher absolute number 
of NK cells in the periphery and these cells displayed a more mature phenotype, suggesting 
that IL-1R8-mediated regulation in NK cells is attributable to the hematopoietic compartment.   
To understand whether the regulatory function of IL-1R8 was NK cell-intrinsic or it was 
dependent on the contribution of other leukocytes, we generated competitive bone-marrow 
chimeric mice transplanting a mix of Il1r8+/+ CD45.1 and Il1r8-/- CD45.2 BM cell in both 
Il1r8+/+ and Il1r8-/- hosts. Il1r8+/+ and Il1r8-/- NK cells in these mice differentiated in the 
same competitive environment and their maturation was consequently driven by the same 
stimuli. Upon reconstitution, the frequency of Il1r8-/- NK cells was higher in the periphery 
and their phenotype was more mature, compared with those of Il1r8+/+ NK cells, in both 
Il1r8+/+ and Il1r8-/- recipients (Figure 5C and 5D).  
Along the same line, co-culture experiments of NK cells with LPS- or CpG-primed dendritic 
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cells (DCs) showed that Il1r8-/- NK cells produced higher IFNγ levels irrespectively of the DC 
genotype (Figure 5E, 5F). 
These results demonstrated that the negative regulation exerted by IL-1R8 was an intrinsic 
mechanism in NK cells and excluded that IL-1R8-deficiency in non-hematopoietic cell types 
or in other leukocytes could lead to the generation of a microenvironment that promoted NK 
cell differentiation.  
 
 
Figure 5. The enhanced maturation and activation of Il1r8-/- NK cell is a cell autonomous mechanism. 
(a and b) Peripheral NK cell absolute number (a) and CD27low NK cell frequency (b) in bone marrow 
chimeric mice upon reconstitution (9 weeks). (c and d) Peripheral NK cell (c) and NK cell subset (d) 
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frequency in competitive chimeric mice transplanted with 50% of Il1r8+/+ CD45.1 cells and 50% of Il1r8-/- 
CD45.2 cells upon reconstitution (9 weeks). Upon reconstitution a defective engraftment (12% instead of 
50% engraftment) of Il1r8-/- stem cells was observed in competitive conditions. (e, f) IFNγ production by 
Il1r8+/+ and Il1r8-/- NK cells upon co-culture with LPS- or CpG-primed Il1r8+/+ and Il1r8-/- DCs. (*p < 0.05, 
**p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
5.1.5 IL-1R8 regulates NK cell differentiation through the inhibition of IL-18 
pathway  
 
The enhanced differentiation of Il1r8-/- NK cells suggested hyper-activation of an IL-1R8-
targeted pathway in this cell type. To dissect the pathway involved, we first considered the 
contribution of MyD88, which is a key transcription factor downstream of any IL-1R8-
targeted molecule. MyD88-deficiency led to a reduced frequency of mature NK cells in the 
spleen, measured as CD11b+ NK cell frequency (Figure 6A). Since IL-18 is one of the major 
cytokines involved in NK cell differentiation and function and is targeted by IL-1R8, we next 
evaluated the role of IL-18 in Il1r8-/- NK cell phenotype. As shown in Figure 6B, the 
depletion of IL-18 in vivo with an anti-IL-18 neutralizing antibody rescued the effect of IL-
1R8-deficiency on NK cell differentiation. Indeed, upon IL-18 neutralization, no difference 
was observed in the frequency of CD27low NK cells between Il1r8+/+ and Il1r8-/- mice. 
Treatment with a control isotype antibody did not affect the enhanced differentiation of NK 
cells in Il1r8-/- mice, compared with Il1r8+/+ mice. In agreement, IL-18 genetic blockade also 
abolished the phenotype observed in Il1r8-/- mice (Figure 6C). Thus, IL-1R8 suppressed IL-
18-mediated stimulation of NK cells and consequently inhibited NK cell maturation.  
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Figure 6. IL-1R8-deficient NK cell phenotype is dependent on IL-18. (a) NK cell maturation in Mydd88-
deficient mice. (b, c) Splenic CD27low NK cell frequency in Il1r8+/+ and Il1r8-/- mice upon IL-18 in vivo 
depletion (b) or in Il18-/-/Il1r8-/- (c). (d) IFNγ production by Il1r8+/+ and Il1r8-/- NK cells upon co-
culture with CpG-primed Il1r8+/+ DCs and IL-18 blockade. (e, f) Peripheral CD27low NK cell frequency in 
wild-type, Il1r8-/-, Il1r1-/- and Il1r8-/-Il1r1-/- mice (e) and IFNγ production by splenic NK cells after IL-12 
and IL-1β or IL-18 stimulation (f). (g,h) Splenic CD27low NK cell frequency in Il1r8+/+ and Il1r8-/- mice 
upon commensal flora depletion (g) and breeding in co-housing conditions (h). (*p < 0.05, **p < 0.01, 
***p < 0.001, Mean ± SEM is represented) 
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Moreover, IL-18 neutralization rescued the enhanced IFNγ production observed in IL-1R8-
deficient NK cells, upon co-culture with CPG-primed DCs, indicating that IL-18 pathway is 
the major target of IL-1R8-mediated regulation of NK cell effector functions (Figure 6D). 
To exclude the involvement of other ILRs and TLRs in the IL-1R8-dependent regulation of 
NK cells, we evaluated the role of IL-1R1 signalling and the contribution of the commensal 
microflora in NK cell differentiation and function, in Il1r8-/- mice. Il1r1-/- mice displayed the 
same NK cell maturation phenotype as wild-type mice and Il1r1-/-/Il1r8-/- mice mimicked the 
phenotype of Il1r8-/- mice, suggesting that IL-1R1 was not one of the IL-1R8 targets in this 
context (Figure 6E). Concerning IL-1-involvement in NK cell activation, we did not observed 
any NK cell activation in terms of IFNγ production, upon stimulation with IL-12 and IL-1β, 
thus excluding IL-1 pathway as a possible target of IL-1R8 in the modulation of NK cell 
maturation and function (Figure 6F). 
Since commensal bacteria are involved in NK cell priming [350], we tested whether IL-1R8 
targeted microbiota-derived signals in NK cells, thus affecting NK cell differentiation. 
Microflora depletion was obtained through oral treatment with antibiotics for 5 weeks and 
confirmed by 16S rRNA qPCR in fecal pellets (data not shown). In agreement with previous 
reports, antibiotic treatment impaired the frequency of the CD27low mature NK subset in both 
Il1r8+/+ and Il1r8-/- mice. However, antibiotic-treatment did not abolish the difference in NK 
cell maturation between Il1r8-/- and Il1r8+/+ mice. This suggests that the regulation of NK cell 
differentiation mediated by IL-1R8 is not dependent on commensal microbiota-derived 
signals, which act through a different mechanism (Figure 6G). Finally, the phenotype of NK 
cells was not modified by co-housing of Il1r8+/+ and Il1r8-/- mice (Figure 6H), in line with the 
irrelevance of commensal flora (Figure 6G) and microenvironment (Figure 5A, B, C, D, E, 
F). 
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5.1.6 IL-1R8 directly inhibits IL-18-dependent pathways in NK cells  
 
The results reported above show that IL-1R8 regulated IL-18 signalling pathway in NK cells, 
thus controlling NK cell maturation and function. Indeed, increased phospho-IRAK4/IRAK4 
ratio was induced by IL-18 in Il1r8-/- NK cells compared to wild type NK cells, indicating 
unleashed early signaling events downstream of MyD88 and therefore myddosome formation 
(Figure 7A). This result is consistent with previous reports regarding the molecular 
mechanism of IL-1R8 activity, including structural analysis. By stimulated emission depletion 
(STED) microscopy, we observed clustering of IL-1R8 and IL-18Rα (Figure 7B), suggesting 
an interaction between the two molecules as indicated by previous studies.  
Since mTOR pathway controls NK cell metabolism and differentiation [351] and it is targeted 
by IL-1R8 in T cells, we analysed the phosphorylation of key molecules downstream of 
mTOR activation (e.g. the translation-initiation factor eIF4E–binding protein 4EBP1 and the 
S6 ribosomal kinase S6K), upon stimulation with IL-18. Given that MAPK/JNK pathway is 
involved in NK cell activation and it is regulated by IL-1R8, we also considered the 
phosphorylation of JNK, in response to IL-18 treatment. As shown in Figure 7C, IL-1R8 
deficiency led to enhanced phosphorylation of S6 and JNK in splenic NK cells, upon 15’ of 
treatment with IL-18. After 30’ of IL-18 stimulation, increased S6 phosphorylation was still 
observed in Il1r8-/- NK cells, whereas JNK phosphorylation returned to the basal level of 
Il1r8+/+ controls, indicating a different kinetics of activation of the two pathways. 
Collectively, these results demonstrated that IL-1R8 inhibited IL-18-dependent activation of 
mTOR and JNK pathways in NK cells and therefore modulated NK cell maturation.  
To obtain a comprehensive picture of the impact of IL-1R8 deficiency on NK cell function 
and in particular on the response to IL-18, we performed RNA-seq analysis. The 
bioinformatic analysis of such a big data needed to be careful addressed and we decided to 
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use the Metascape software to get unbiased information of the differentially expressed genes 
and thus enriched pathways in IL-1R8-deficient NK cells.As shown in Figure 8A, IL-1R8 
deficiency had a profound impact on the transcriptional profile of NK cells, both at steady 
state conditions and upon stimulation with IL-18. In particular, the enriched pathways 
observed in IL-18-stimulated NK cells in absence of IL-1R8 included NK cell responsiveness, 
cytotoxicity, cytokine production and MAPK activation (Figure 8B). 
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Figure 7. IL-1R8-mediated regulation of IL-18 pathway. (a) IRAK4 phosphorylation rate in Il1r8+/+ and 
Il1r8-/- NK cells upon stimulation with IL-18. (b) STED microscopy of human NK cells stimulated with IL-
18. Magnification bar: 2µm. (c) S6, 4EBP1 and JNK phosphorylation in Il1r8+/+ and Il1r8-/- NK cells upon 
stimulation with IL-18. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
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Figure 8. IL-18 responsiveness in Il1r8+/+ and Il1r8-/- NK cells. (a) RNA-seq analysis of resting and IL-
18-activated Il1r8+/+ and Il1r8-/- NK cells. Differentially expressed (p<0.05) genes are shown. FC: fold 
change. (b) Metascape analysis of enriched gene pathways of resting and IL-18-activated Il1r8+/+ and 
Il1r8-/- NK cells. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
5.1.7 IL-1R8 regulates human NK cell activation 
 
As discussed above and shown in Figure 1A-E, IL-1R8 relative expression in human NK cells 
and during NK cell maturation mirrors that observed in the mouse. It was therefore important 
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to obtain indications that in human NK cells IL-1R8 acts as a checkpoint for activation.  First, 
we retrospectively analyzed IL-1R8 expression in relation to responsiveness to a combination 
of IL-18 and IL-12 in a series of normal donors. As shown in Figure 9A, we observed an 
inverse correlation between IL-1R8 levels and IFNγ production in peripheral blood NK cells 
(r2=0.7969, p=0.0012). To assess whether the functional role of IL-1R8 was conserved in 
human NK cells, we have tried to transfect human primary cells and human NK cell lines 
(e.g. NKL and NK-92) with several RNA- and DNA-based constructs to silence IL-1R8. We 
failed to transfect human NK cells by using commonly used transfecting system. In particular, 
we tested siRNA, Stealth RNAi™ siRNA (Invitrogen) and a CRISPR-Cas9 system, 
transfecting with Lipofectamin, Lipofectamine® RNAiMAX (Invitrogen) or Amaxa® 
Nucleofector® Technology (Lonza). We have also tried using a Lentiviral infection system, 
but the vitality of cells and the infection efficiency were too low. Finally, we succeeded in 
peripheral blood NK cell transfection using siRNA delivered with the Accell™ medium (GE 
Healthcare). IL-1R8 partial silencing was associated with a significant increase of CD69 
expression and IFNγ production (Figure 9B). These results suggest that in human NK cells as 
in murine counterparts IL-1R8 works as a negative regulator of activation and that its 
inactivation unleashes human NK cell effector function. 
 
 
 
Figure 9. IL-1R8-mediated regulation of human NK cells. (a) Correlation between IL-1R8 expression 
and IFNγ production in human peripheral blood NK cells. The analysis was conducted retrospectively in 
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all 9 normal donors tested for response to IL-18 and IL-12. (b) IL-1R8 and CD69 expression and IFNγ 
production in human NK cells 7 days after transfection with control siRNA or IL-1R8-specific siRNA in 
duplicate. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
 
 
5.2 Relevance in cancer and metastasis 
5.2.1 IL-1R8 inhibits NK cell anti-tumor potential in liver cancer 
 
To address the in vivo relevance of IL-1R8-dependent negative regulation of NK cell effector 
functions, we examined anti-cancer and anti-viral resistance. Since the liver is characterized 
by a high frequency of NK cells [149], we first focused on liver carcinogenesis. We therefore 
addressed whether IL-1R8-deficiency could favour NK cell activity in a model of 
Diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) and we analysed the 
susceptibility of Il1r8-/- mice in DEN-induced HCC. IL-1R8-deficient female and male mice 
were protected against the development of HCC, in terms of macroscopic number and size of 
lesions (Figure 10A, 10B). The liver macroscopic score was lower in female mice, in 
agreement with estrogen-dependent gender disparity in this model [352]. The protection 
against the development of HCC in the absence of IL-1R8 was confirmed by histological 
analysis, showing significantly higher number of dysplastic (p=0.02) and adenoma (p=0.005) 
lesions in 10 month-old HCC-bearing wild type males compared to IL-1R8-deficient hosts 
(Table 1). The analysis of leukocyte infiltrate by flow cytometry and immunohistochemistry 
showed that the percentage of NK cells among liver CD45+ cells and the absolute number 
were higher in Il1r8-/- HCC-bearing mice (Figure 10C, 10D). In addition, the percentage of 
IFN-γ+ NK cells was higher in the liver, but not in the spleen of Il1r8-/- mice (Figure 10E). 
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Figure 10. Phenotype of DEN-induced HCC in IL-1R8-deficient mice. (a, b) Macroscopic score of liver 
lesions in female (a) and male (b) Il1r8+/+ and Il1r8-/- mice 6, 8, 10 and 12 months after DEN injection. (c, 
d) Frequency (c) and representative histological quantification (d) of NK cell infiltrate in livers of 
Il1r8+/+ and Il1r8-/- tumor bearing mice (20X, bar = 100µm). 
(e) Frequency of IFNγ+ NK cells in liver and spleen of Il1r8+/+ and Il1r8-/-  tumor bearing mice. 
(*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
 
T cell subsets were not appreciably altered in normal and tumor bearing Il1r8-/- mice (not 
shown). Finally, increased levels of cytokines involved in anti-tumor immunity (e.g. IFNγ) 
and a reduction of pro-inflammatory cytokines associated with tumor promotion (IL-6, TNFα, 
IL-1β, CCL2, CXCL1) were observed (Table 2). Importantly, to address the direct role of IL-
1R8-deficient NK cells in the protection, we depleted NK cells in Il1r8+/+ and Il1r8-/- DEN- 
treated mice using an anti-NK1.1 neutralizing antibody. The depletion of NK cells abolished 
the protection against liver carcinogenesis observed in both male and female Il1r8-/- mice 
(Figure 11A, 11B), demonstrating that IL-1R8 deficiency enhanced NK cell antitumor 
potential in the model of DEN-induced HCC.  
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 8 Months 10 Months 12 Months 
 Number of lesions, 
mean ± (SEM) 
 Number of lesions, 
mean ± (SEM) 
 Number of lesions, 
mean ± (SEM) 
 
 Lesion Il1r8
+/+
 Il1r8
-
/-
 
p Il1r8
+/+
 Il1r8
-
/-
 
p Il1r8
+/+
 Il1r8
-
/-
 
p 
Displasia 5.4 ± (1.3)  3.6 ± (1.4) 
0.26 7.8 ± (1.0) 6.0 ± (1.4) 
0.02 6.3 ± (0.8) 3.4 ± (0.8) 
0.03 
 Adenoma 1.3 ± (0.49) 0.37 ± (0.1) 
0.3 3.2 ± (0.7) 0.9 ± (0.3) 
0.005 3.0 ± (0.7) 1.0 ± (0.2) 
0.06 
Carcinoma 0.0 ± (0.0) 0.0 ± (0.0) 
nd 0.0 ± (0.0) 0.07 ± (0.0) 
nd 0.12 ± (0.0) 0.1 ± (0.1) 
nd 
Table 1. Histological analysis of HCC-bearing mice. 
Number of lesions in Il1r8+/+ and Il1r8-/- HCC-bearing mice is listed. 
 
 6 months after DEN 8-10 months after DEN 12 months after DEN 
Cytokine 
pg/mL  
Il1r8 +/+ 
n=4-5* 
Il1r8 -/- 
n=5 
p 
value 
Il1r8 +/+ 
n=7-10* 
Il1r8 -/- 
n=9-10* 
p 
value 
Il1r8 +/+ 
n=3-5* 
Il1r8 -/- 
n=3-5* 
p 
value 
IL-23 
 
173.1 ± 
29.12 
 
247.3 ± 
15.16 
0.05 187.7 ± 
13.47 
343.4 ± 
66.29 
0.04 103.7 ± 
26.72 
138.6 ± 
37.51 
0.47 
IL-12p70 277.6 ± 
44.49 
 
358.4 ± 
12.44 
0.12 
 
293 ± 
16.31 
 
357.2 ± 
34.77 
0.13 
 
152 ± 
20.14 
164.9 ± 
15.22 
0.62 
 
IL-17A 
 
69.98 ± 
9.88 
 
95.03 ± 
6.44 
0.07 56.41 ± 
7.46 
102.4 ± 
19.01 
0.04 38.13 ± 
10.39 
45.05 ± 
8.78 
0.62 
 
IFNγ 
 
295 ± 
72.78 
 
385.4 ± 
48.6 
0.32 
 
357.5 ± 
57.63 
593.2 ± 
84.33 
0.05 
 
195.4 ± 
65.29 
243.3 ± 
104 
0.72 
 
IL-6 
 
90.37 ± 
6.45 
 
67.23 ± 
9.79 
0.08 
 
126.9 ± 
19.52 
69.64 ± 
6.93 
0.01 
 
61.24 ± 
18.05 
42.28 ± 
12.17 
0.44 
 
IL-1β 
 
91.99 ± 
5.23 
 
58.68 ± 
7.29 
0.006 
 
142.4 ± 
28.24 
60.35 ± 
4.42 
0.01 
 
47.66 ± 
14.08 
29.81 ± 
7.66 
0.31 
 
TNFα 
 
163.5 ± 
7.16 
 
92.06 ± 
21.04 
0.01 
 
194.6 ± 
28.03 
100.1 ± 
14.24 
0.008 
 
94.77 ± 
14.24 
57.45 ± 
14.51 
0.13 
 
CCL2 
 
32.51 ± 
1.54 
 
24.1 ± 
5.64 
0.19 
 
43.97 ± 
7.25 
25.42 ± 
1.37 
0.02 
 
28.1 ± 
4.99 
 
19.72 ± 
1.23 
0.14 
 
CXCL1 
 
197.6 ± 
8.85 
142.5 ± 
20.93 
0.04 
 
183.4 ± 
17.75 
123.7 ± 
10.5 
0.01 
 
105.6 ± 
6.49 
77.86 ± 
9.64 
0.04 
 
Liver 
enzymes**  
         
ALT  142.5± 
52.5  
0.00 ± 
0.00,  
0.004 111.7± 
70.77*** 
60.0 ± 
35.0*** 
0.32 0.00 ± 
0.00 
0.00 ± 
0.00 
NA 
 
AST  159.6± 
39.79 
101.0 ± 
1.87  
0.18 134.0± 
15.28*** 
97.0 ± 
8.0*** 
0.06 105.0± 
25.45 
89.0 ± 
5.1 
0.55 
 
*: Samples with not detectable levels were not included in the analysis. 
 
 
100 
**: levels are U/L. 
***: n=5, 8 months after DEN 
Table 2. Serum cytokine and liver enzyme levels in HCC-bearing mice. 
Cytokines and ALT-AST were detected in sera of Il1r8+/+ and Il1r8-/- HCC-bearing mice at different time-points. 
 
 
 
Figure 11. IL-1R8-deficient NK cells are protective against DEN-induced HCC. (a, b) Macroscopic 
score of liver lesions in female (a) and male (b) Il1r8+/+ and Il1r8-/- mice upon NK cell depletion. (*p < 
0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
 
5.2.2 IL-1R8 inhibits NK cell anti-metastatic activity 
 
NK cells play a major role in controlling hematogenous metastases and we therefore 
addressed the role of IL-1R8 in NK cells a model of sarcoma-derived lung metastases and a 
model of colon cancer-derived liver metastases. The 3-MCA derived fibrosarcoma cell line 
MN-MCA3 was injected intramuscularly in Il1r8+/+ and Il1r8-/- mice and primary tumor 
growth and lung-metastasis were analysed. As shown in Figure 12A, the number of lung 
metastases was significantly lower in Il1r8-/- mice 25 days upon MN-MCA3 injection, 
whereas we did not observed difference in primary tumor growth between the two groups 
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(Figure 12B). The frequency of total NK cells and mature CD27low NK cells was higher in 
Il1r8-/- lungs (Figure 12C and 12D). To address the involvement of NK cells in the protection 
observed in Il1r8-/- mice, we depleted NK cells treating mice with a specific anti-NK1.1 
antibody in vivo. We then performed in vivo imaging 3-dimensional analysis through 
Fluorescence Molecular Tomography (FMT) technology, which is based on 2-deoxyglucose 
(2-DG) fluorescence. Through this technique it is possible to obtain a precise localization of 
the tumor and a quantification in deep tissue. 2-DG is a glucose molecule, with the 2-
hydroxyl group replaced by hydrogen, in order not to undergo further glycolysis and it 
selectively marks cells with a high glucose uptake, such as tumor cells. The fluorescent 
substrate was injected i.v. in the animal 24 hours and the analysis was performed using a 
trans-illuminator. The signal in the lung showed that the protection was completely abolished 
in NK cell-depleted Il1r8-/- mice. This result was also confirmed by macroscopic count of 
lung metastases. (Figure 12E, 12F). To address the involvement of IL-18/IL-18R axis in IL-
1R8-dependent regulation of NK cells in this model, we neutralized IL-18 and IFNγ in 
sarcoma-bearing mice, for the entire duration of the experiment. As shown in the new Figure 
12G, both IFNγ and IL-18 neutralization abolished or dramatically reduced the phenotype of 
IL-1R8-deficient mice. On the contrary, IL-1R1/IL-1R8-double deficient mice showed the 
same phenotype as IL-1R8-deficient mice, indicating that IL-1 signaling did not contribute to 
the protection. Since IL-1R8 is known to be involved in Th17 cell polarization and it is 
expressed by both CD4 and CD8 T cells (Figure 1A, 1B, 1F), we depleted IL-17A and 
CD4/CD8 to assess the role of T cells in IL-1R8-mediated protection. The depletion of T 
lymphocytes or the effector molecule IL-17A did not impact on the protective role of IL-1R8-
deficiency in the control of metastases, even though the depletion of T cells caused an 
increased number of lung metastases in wild-type mice. Moreover, we did not observe any 
difference in T cell frequency and T cell subsets (i.e. naïve, effector and memory cells) in IL-
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1R8-deficient mice compared to wild-type mice, either in lung or in spleen of tumor-bearing 
mice (not shown). 
 
 
Figure 12. Role of IL-1R8 in NK cell anti-metastatic activity. (a) Number of spontaneous lung metastasis 
in Il1r8+/+ and Il1r8-/- mice (25 days after i.m. injection of the MN/MCA1 sarcoma cell line). (b) 
MN/MCA1 primary tumor growth in Il1r8+/+ and Il1r8-/- mice. (c, d) NK cell (c) and NK cell subset (d) 
frequency in the lungs of Il1r8+/+ and Il1r8-/- MN/MCA1 tumor bearing mice. (e, f) 2-DG quantification 
(e) and number of metastases (f) in lungs of Il1r8+/+ and Il1r8-/- tumor bearing mice upon NK cell 
depletion. (g) Number of lung metastasis in Il1r8+/+ and Il1r8-/- MN/MCA1 sarcoma bearing mice upon 
after IFNγ or IL-18 neutralization. (h) Number of lung metastases in Il1r8+/+ and Il1r8-/-, Il1r1-/-, Il1r1-/-
/Il1r8-/- MN/MCA1-bearing mice. (i) Volume of lung metastases in Il1r8+/+ and Il1r8-/- MN/MCA1-bearing 
mice upon depletion of IL-17A or CD4+/CD8+ cells. (j) Number of liver metastases in Il1r8+/+ and Il1r8-/- 
MC38 colon carcinoma bearing mice. (k) Number of liver metastases in Il1r8+/+, Il1r8-/-, Il18-/-, Il18-/-
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/Il1r8-/- MC38 colon carcinoma bearing mice. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is 
represented) 
 
 
Liver metastasis is a major problem in the progression of colorectal cancer and we therefore 
assessed the potential of Il1r8-/- NK cells to protect against liver metastasis using the MC38 
colon carcinoma cell line injected in the spleen. As shown in Figure 12J, Il1r8-/- mice were 
protected against MC38 colon carcinoma liver metastasis and in addition, IL-18-genetic 
deficiency abrogated the protection observed in Il1r8-/- mice (Figure 12K), indicating that the 
IL-1R8-dependent control of MC38-derived liver metastasis occurs through the IL-18/IL-18R 
axis.  
Finally, to assess the primary role of Il1r8-/- NK cells in the cancer protection, adoptive 
transfer was used. Adoptively transferred NK cells were detectable 3 and 7 days after 
injection (Figure 13A, 13B), they displayed proliferative capacity (Figure 3C) and were fully 
functional, in terms of IFNγ production and degranulation after ex vivo stimulation (Figure 
3D, 3E). Interestingly, degranulation and IFNγ production were significantly higher in Il1r8-/- 
NK cells (Figure 3D, 3E). As shown in Figure 13F-H, adoptive transfer of Il1r8+/+ NK cells 
had no effect on lung and liver metastasis. In contrast, adoptive transfer of Il1r8-/- NK cells 
significantly and dramatically reduced the number and volume of lung and liver metastasis 
(Figure 13F-H). The anti-metastatic activity of Il1r8-/- NK cells was particularly evident in 
the liver colorectal metastasis model, with 47 ± 13 secondary lesions in control mice and 5 
out of 6 mice free of secondary lesions in mice transferred with Il1r8-/- NK cells (Figure 13H). 
Given the natural history and clinical challenges of colorectal cancer, this observation has 
potential translational implications. Thus, IL-1R8 genetic inactivation unleashes NK cell 
mediated resistance to carcinogenesis in the liver and amplifies the anti-metastatic potential of 
these cells in liver and lung in a NK cell-autonomous manner. 
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Figure 13. Adoptive transfer of Il1r8+/+ and Il1r8-/- NK cells in tumor bearing mice. (a, b) Il1r8+/+ and 
Il1r8-/- NK cell absolute number three or 7 days after adoptive transfer. (c) In vivo Il1r8+/+ and Il1r8-/- NK 
cell proliferation three days after adoptive transfer. (d, e) Ex vivo IFNγ production (d) and degranulation 
(e) upon 4-hour stimulation with PMA-Ionomycin, IL-12 and IL-18 in adoptively transferred Il1r8+/+ and 
Il1r8-/- NK cells. (f, g) Number (f) and volume (g) of lung metastases of Il1r8+/+ MN/MCA1 sarcoma 
bearing mice after adoptive transfer of Il1r8+/+ and Il1r8-/- NK cells. (h) Number of liver metastases of 
Il1r8+/+ MC38 colon carcinoma bearing mice after adoptive transfer of Il1r8+/+ and Il1r8-/- NK cells. 
(*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
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5.3 Relevance in viral infection 
5.3.1 IL-1R8-deficiency is associated with a more efficient viral control in liver 
 
MCMV infection is a well-characterized model that resembles the systemic and controlled 
viral infections in immunocompetent individuals. To investigate whether IL-1R8 regulates 
NK cell effector functions in the context of viral infections, we analyzed MCMV control and 
NK cell activity in Il1r8+/+ and Il1r8-/- MCMV-infected mice. In particular, we infected mice 
with wild-type and Δm157 MCMV, a mutant virus with a deletion of the m157 gene that 
compromises virus control by Ly49H+ NK cells, which recognize the viral-encoded protein 
m157 and consequently undergo proliferation and activation.  
We infected wild-type and IL-1R8-deficient mice intravenously with 5x105 PFU of wild-type 
and Δm157 MCMV to characterize the viral control in presence or in absence of IL-1R8. 
Viral load was determined by plaque assay in the homogenates of liver, lung and spleen. As 
shown in Figure 14A, the liver viral titer was lower in Il1r8-/- compared to Il1r8+/+ mice  in 
both infections and both time-points, indicating that IL-1R8-deficient mice were able to clear 
the virus more efficiently. In lung and spleen no difference in terms of viral titer was 
observed. 
 
 
 
Figure 14. MCMV titer in Il1r8+/+ and Il1r8-/- mice. (a-c) Viral titer assessed by plaque assay in liver 
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(a), spleen (b) and lung (c), 1.5 and 4.5 days post infection with wild-type and Δm157 MCMV. (*p < 0.05, 
**p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
 
5.3.2 IL-1R8-deficient NK cells displayed enhanced effector functions after 
infection 
 
To assess whether NK cells were involved in the antiviral protection, we analyzed NK cell 
effector functions in liver and spleen upon infection. As shown in Figure 15, NK cells 
displayed enhanced effector functions in absence of IL-1R8, at day 1.5 post infection. Indeed, 
in case of infection with wild-type MCMV, 1.5 days post infection correspond to the peak of 
the innate immune response. At 4.5 days post infection the virus is controlled and indeed NK 
cell activity decreased. IL-1R8-deficient NK cells produced higher levels of IFNγ in both  
liver (Figure 15A) and spleen (Figure 15B) and degranulated more in both liver (Figure 15C) 
and spleen (Figure 15D), at day 1.5 post infection. A more sustained NK cell activation in 
terms of IFNγ (Figure 15B) and degranulation (Figure 15D) was also observed in case of 
Δm157 infection in spleen. No difference in terms of Granzyme B production was observed 
between Il1r8+/+ and Il1r8-/- mice upon infection (Figure 15E, 15F). Perforin production 
increased in Il1r8-/- mice in spleen (Figure 15H), but not in liver (Figure 15G), at day 1.5 post 
infection, in both WT and Δm157 infections. Interestingly, NK cell degranulation (Figure 
15C), Granzyme B (Figure 15E) and Perforin (Figure 15G) production was lower in Il1r8-/- 
mice 4.5 days post infection, in case of WT MCMV. NK cell activation decreases during viral 
clearance and the reduced NK cell activation observed in Il1r8-/- mice reflected a more 
efficient viral control in absence of IL-1R8. Moreover, we analyzed cytokine levels in sera of 
infected mice (Figure 16). 
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Figure 15. NK cell effector functions in infected mice. (a-h) Frequency of IFNγ+ (a, b), CD107a+ (c, d), 
GranzymeB+ (e, f) and Perforin+ (g, h) NK cells in liver (a, c, e, g) and spleen (b, d, f, h) of Il1r8+/+ and Il1r8-/- 
infected mice (1.5 and 4.5 days post infection), with wild-type and Δm157 MCMV. (*p < 0.05, **p < 0.01, 
***p < 0.001, Mean ± SEM is represented) 
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Figure 16. Serum cytokine levels in infected mice. Cytokine serum levels in Il1r8+/+ and Il1r8-/- infected mice 
(1.5 and 4.5 days post infection), with wild-type and Δm157 MCMV. (*p < 0.05, **p < 0.01, ***p < 0.001, 
Mean ± SEM is represented) 
 
 
Levels of pro-inflammatory cytokines (i.e. TNFα, IL-12p70, IL-6, IL-10, CCL2) were 
reduced in Il1r8-/- mice, reflecting the reduced viral titer. Interestingly, IFNγ, which is an 
important anti-viral mediator produced by cytotoxic lymphocytes including NK cells, was 
detected at higher levels in sera of IL-1R8-deficient mice (Figure 16). This is consistent whit 
0
100
200
300
400
500
IL-
12
p7
0 (
pg
/m
l)
1.5 p.i. 4.5 p.i. 1.5 p.i. 4.5 p.i.φ
Il1r8+/+
Il1r8 -/-
** **
0
500
1000
1500
2000
1.5 p.i. 4.5 p.i. 1.5 p.i. 4.5 p.i.φ
IFN
g (
pg
/m
l)
*
**
0
50
100
150
200
1.5 p.i. 4.5 p.i. 1.5 p.i. 4.5 p.i.φ
IL-
10
 (p
g/m
l)
0
50
100
150
1.5 p.i. 4.5 p.i. 1.5 p.i. 4.5 p.i.φ
TN
Fa
 (p
g/
m
l) **
*
0
100
200
300
400
500
1.5 p.i. 4.5 p.i. 1.5 p.i. 4.5 p.i.φ
IL-
6 (
pg
/m
l)
**
0
5000
10000
15000
1.5 p.i. 4.5 p.i. 1.5 p.i. 4.5 p.i.φ
M
CP
-1
 (p
g/
m
l) ** *
WT MCMV WT MCMVΔm157 MCMV Δm157 MCMV
 
 
109 
the more efficient viral control observed in Il1r8-/- mice and the enhanced IFN-γ production 
observed intracellularly in NK cells in liver and spleen.  
Collectively, these results indicated that IL-1R8-deficient mice are protected against MCMV 
infection and this correlated with increased NK cell activation.  
5.3.3 The protection observed in IL-1R8-deficient mice is dependent on NK 
cells 
 
To demonstrate whether the protection we observed in Il1r8-/- mice was directly dependent on 
NK cells and not influenced by other cell types expressing IL-1R8, we first analyzed the 
involvement of T cells in the phenotype, since T cells are crucial mediators of antiviral 
activities. We observed that the depletion of T cells did not affect the protection in liver 
(Figure 17A) and IFNγ production was not altered in absence of IL-1R8, in both liver and 
spleen, upon stimulation with specific viral-encoded peptides (i.e. m38 and m45) (Figure 
17B-17E). This indicated that T cells were not involved in the viral attenuation observed in 
the absence of IL-1R8. However, since CMV is mainly controlled by NK cells, we cannot 
exclude the role of IL-1R8 in T lymphocytes in viral models where the T cell-mediate 
response is relevant.  
To directly demonstrate that IL-1R8-deficient NK cells were responsible for the viral 
attenuation, we performed adoptive transfer of sorted NK cells (NK1.1+ CD3-) in newborn 
mice, which were infected at day 1 after birth and transferred with NK cells at day 2 post 
infection. We decided to use newborn mice, instead of adult mice, to avoid the control of 
MCMV mediated by endogenous NK cells that occurs in adult immune-competent mice. In 
newborn mice, NK cells are not differentiated yet and the virus is not controlled. As shown in 
Figure 18, the transfer of IL-1R8-deficient NK cells provided protection in liver, spleen, lung 
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and brain, demonstrating that IL-1R8 plays a key role in the regulation of NK cell antiviral 
activities. The protection observed in the brain is particularly important in the context of the 
congenital infection of CMV, in which the virus infects the developing fetus and can reach 
the CNS, causing long-term neurodisorders. 
 
 
Figure 17. T cell contribution in MCMV infection. (a) Viral titer in liver of Il1r8+/+ and Il1r8-/- infected 
mice at day 4.5 post infection, upon CD4+/CD8+ T cell depletion. (b-e) IFNγ production by CD8+ T cells 4 (b, c) 
and 7 days post infection (d, e), in liver (b, d) and spleen (c, e), upon stimulation with m38 and m45 
peptides. (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
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Figure 18. NK cell adoptive transfer in newborn infected mice. (a-d) Viral titer in liver (a), spleen (b), lung 
(c) and brain (d) of newborn wild type mice upon adoptive transfer of Il1r8+/+ and Il1r8-/- NK cells (7 days post 
infection). (*p < 0.05, **p < 0.01, ***p < 0.001, Mean ± SEM is represented) 
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6. Discussion and future perspectives 
 
Unleashing or redirecting the effector functions of NK cells, and in general of cytotoxic 
lymphocytes, is a promising approach in oncology that has recently led to improved 
treatments for several types of cancer. It is based on the fundamental concept of readdressing 
the equilibrium of activating and inhibitory signals, which regulate the immune system in 
physiological and pathological conditions [215]. In this study, we focus on the role of IL-1R8, 
a negative regulator of the IL-1 family, in NK cells and we addressed the relevance of IL-1R8 
blockade to sustain and enhance NK cell antitumor and antiviral activities.  
We showed that human and murine NK cells expressed high levels of IL-1R8 and it was 
acquired during the maturation process, in line with other inhibitory receptors. Indeed, the 
expression of negative regulators increases in mature NK cells, which display a lower 
threshold of activation and need to be finely regulated. Compared to other leukocytes, NK 
cells expressed higher levels of IL-1R8, mirroring the necessity of a quick and strong 
inhibition, to avoid an uncontrolled and detrimental response.  
IL-1R8-deficient NK cells displayed a more mature phenotype and enhanced effector 
functions, in terms of IFNγ and GranzymeB production, FasL expression and degranulation, 
upon stimulation ex-vivo. Moreover, NK cells expressed higher levels of activating receptors 
(NKG2D, DNAM-1 and Ly49H) at steady-state conditions. This indicated that IL-1R8 
mediates a regulatory signal, part of the wide spectrum of inhibitory signals that 
counterbalance the strong cytotoxic potential of NK cells. In absence of IL-1R8, NK cells are 
hyper-responsive to inflammatory signals, displaying a lower threshold of activation.  
Competitive bone marrow chimeric mice and depletion experiments demonstrated that IL-
1R8 directly acts on NK cells, blocking IL-18 signaling. Thus, IL-1R8 acts as an inhibitor of 
NK cell maturation and effector functions, by tuning IL-18-dependent activation. Bone 
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marrow precursor analysis and NK cell phenotyping in newborn mice showed that IL-1R8-
mediated regulation in NK cells is an early and central event, acting in the first stages of NK 
cell development, but not affecting NK cell precursors. Indeed, IL-18-driven signaling, which 
is regulated by IL-1R8, is not considered one of the major modulators of NK cell 
development and mainly acts in differentiated NK cells [108]. The absence of IL-1R8 
determines enhanced and IL-18-driven NK cell maturation, suggesting that an uncontrolled 
signal of IL-18 in NK cells leads to a mature and hyper-active phenotype. 
Other than IL-18, IL-1- and TLR-signaling are regulated by IL-1R8 and could potentially 
favor NK cell maturation in absence of IL-1R8. Deficient mice demonstrated that IL-1 was 
not involved in the enhanced NK cell maturation observed in IL-1R8-deficient mice. Since 
Il1r8-/- NK cells displayed a more mature phenotype at steady-state conditions, we infer that 
TLR signaling could be driven by commensal-derived agonists. In line with previous reports, 
flora depletion experiments showed that the microbiota was involved in the stimulation of NK 
cell maturation, but it was not responsible for the enhanced NK cell maturation observed in 
absence of IL-1R8. This is possibly due to the fact that instructive signals derived from the 
microbiota may not have a direct effect on NK cells, as shown by Ganal SC et al. and the role 
of IL-18 is predominant in IL-1R-deficient NK cells [350]. 
IL-1R8 therefore emerges as a modulator of NK cell activities and to give relevance to this 
finding, we investigated the significance of IL-1R8 in the regulation of NK cell effector 
functions in models of NK cell-mediated immunesurveillance: cancer and viral infections.  
NK cells play an important role in the innate immune response against tumor metastasis, 
whereas the control of solid tumors by NK cells is normally poorly efficient. Nevertheless, 
NK cell-based immunotherapy approaches that enhance NK cell activation lead to liver 
carcinoma rejection in the mouse and several clinical trials are ongoing. 
In a model of DEN-induced liver carcinogenesis, we observed that IL-1R8-deficiency 
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determined a reduced tumor development and progression, in terms of number of lesions and 
disease severity. The depletion of NK cells led to a rescue of the phenotype, indicating that 
IL-1R8 blocks NK cell antitumoral activity against liver primary tumor. We next analyzed a 
model of lung metastases and IL-1R8-deficient mice were protected from the development of 
lung metastasis, derived from a fibrosarcoma cell line (MN-MCA-1), injected in the muscle. 
The protection was completely abolished upon NK cell depletion. This indicates that, in the 
absence of IL-1R8, NK cells acquire a stronger anti-metastatic activity and are responsible for 
the reduced susceptibility of IL-1R8-deficient mice. It is important to note that the depletion 
of NK cells in wild-type mice did not affect the susceptibility to both lung metastasis and 
HCC, in line with the hypothesis that NK cell-mediated protection is not sufficient in cancer 
models and in patients with established tumors. Interestingly, IL-1R8-deficient NK cells 
acquire the ability to be protective in both models. Given that colorectal cancer-derived liver 
metastases are the major clinical issue in the treatment of colorectal cancer patients, we 
addressed the role of IL-1R8 in NK cells in a model of colon cancer-derived liver metastases. 
In this model, IL-1R8-deficient mice were protected from the development of liver 
metastases. Importantly, the adoptive transfer of IL-1R8-deficient NK cells provided 
protection in both lung and liver metastasis models, suggesting a translational potential of this 
treatment, in the context of NK cell-based immunotherapy. 
In a model of viral infection (MCMV), we observed less susceptibility in absence of IL-1R8, 
associated with increased NK cell effector functions in liver. This indicates that IL-1R8 is 
responsible for blocking NK cell antiviral activities, as well. The control of MCMV is 
particularly important in immunecompromised individuals and in case of bone marrow 
transplantation, the reactivation of the virus is associated with worst outcome [306].  
IL-1R8 therefore emerges as a checkpoint of NK cell effector functions and the blockade of 
this molecule might represent a promising immunotherapeutic approach, aimed at enhancing 
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NK cell antitumoral and antiviral activity. Importantly, the partial silencing of IL-1R8 in 
human primary NK cells was associated with enhanced effector functions and IL-1R8 
expression level in NK cells was inversely correlated with IFNγ production in healthy donors. 
This indicates that IL-1R8 activity in NK cells is conserved in humans, giving relevance to 
IL-1R8 blockade in cancer therapies.  
IL-1R8-deficient mice show exacerbated inflammation in response to ILR and TLR signaling, 
which can promote cancer and since we used IL-1R8 total knock-out mice, the protective 
effect we observed in the liver and lung might be an underestimation of the potential activity 
of IL-1R8-deficient NK cells.  
It is important to note that NK cell hyper-activation may be detrimental in certain conditions 
and the regulation of NK cell reactivity exerted by inhibitory molecules is necessary to avoid 
unspecific and autoimmune responses. Indeed, certain KIR/HLA haplotypes are associated 
with enhanced NK cell activation and autoreactivity that can lead to autoimmune reactions 
[328]. Nevertheless, in patients with malignancies the enhanced activation of antitumoral 
activities represents the major clinical need, even though potential autoimmune reactions need 
to be taken into account. In this regard, the next step of this investigation will be the 
characterization of IL-1R8 in human NK cells in pathological conditions to understand its 
eventual modulation and its role in regulating NK cells in contexts where NK cell effector 
functions can be hampered, such as hematological malignancies and liver cancer. We will 
also characterize the correlation of IL-1R8 expression in NK cells with clinical outcome in 
patients and we will then develop and test blocking reagents for the specific inhibition of the 
molecule in NK cells. Finally, it will be interesting to characterize the potential role of IL-1R8 
in the other subsets of innate lymphoid cells (non NK-ILC1, ILC2 and ILC3) and cytotoxic T 
cells. 
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